1	IN THE UNITED STATES DISTRICT COURT
2	FOR THE EASTERN DISTRICT OF VIRGINIA
3	RICHMOND DIVISION
4	
5	
6	ePLUS, INC. : Civil Action No. : 3:09CV620
7	vs. :
	LAWSON SOFTWARE, INC. : September 7, 2010
8	;
9	
10	COMPLETE TRANSCRIPT OF THE MOTIONS HEARING
11	BEFORE THE HONORABLE ROBERT E. PAYNE
12	UNITED STATES DISTRICT JUDGE
13	
14	APPEARANCES:
15	Scott L. Robertson, Esquire Michael G. Strapp, Esquire
16	Jennifer A. Albert, Esquire Goodwin Procter, LLP
17	901 New York Avenue NW Suite 900
18	Washington, D.C. 20001
19	Craig T. Merritt, Esquire Henry I. Willett, III, Esquire
20	Christian & Barton, LLP
21	909 East Main Street Suite 1200
22	Richmond, Virginia 23219-3095 Counsel for the plaintiff
23	
24	Peppy Peterson, RPR
25	Official Court Reporter United States District Court

```
APPEARANCES: (cont'g)
 1
 2
     Dabney J. Carr, IV, Esquire
     Troutman Sanders, LLP
 3
     1001 Haxall Point
     Richmond, Virginia 23219
 4
     Daniel W. McDonald, Esquire
     Kirstin L. Stoll-DeBell, Esquire
 5
     Merchant & Gould, PC
     80 South Eighth Street
 6
     Suite 3200
     Minneapolis, Minnesota 55402
 7
     Counsel for the defendant
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```

PROCEEDINGS

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

ePlus.

1

THE CLERK: Civil action number 3:09CV00620, ePlus Incorporated versus Lawson Software Incorporated. Will counsel please state their names for the record and identify the parties they represent.

MR. MERRITT: Craig Merritt for ePlus, Your Honor.

MR. ROBERTSON: Scott Robertson from Goodwin Procter for plaintiff, ePlus.

MR. CARR: Dabney Carr for Lawson Software.

MR. McDONALD: Dan McDonald for Lawson Software.

MR. STRAPP: Michael Strapp, Goodwin Procter, for

MS. ALBERT: Jennifer Albert, Goodwin Procter, for ePlus.

MR. WILLETT: Henry Willett, Christian Barton, for ePlus.

THE COURT: We'll see if we can do something to get it a little colder in here for you.

MS. STOLL-DeBELL: Sorry. Kirstin Stoll-DeBell with Merchant & Gould for defendant Lawson Software.

THE COURT: Would you ask if they can do something for moderation.

THE CLERK: Yes, sir.

THE COURT: I can't understand why we can't find a

24

25

happy medium in here.

THE CLERK: You don't think if we let arguments go on for awhile it will get a little warmer?

THE COURT: I thought the presence of all these bodies would do it, but I'm not hopeful. All right. We have the Green issue, the all-damages-at-trial issue, and the expert reports of Staats and Knuth issue. Are there any other issues we need to solve today?

MR. McDONALD: No, Your Honor.

THE COURT: All right. Let's take Mr. Green's report issue.

MR. STRAPP: Good morning, Your Honor. I'd like to make three points regarding our motion to strike Green to focus Your Honor's attention on what we consider to be the most important themes in these motions.

First, we believe that the benchmark for Mr. Green's reasonable royalty analysis is the Lawson/IBM agreement which the Court has already excluded from evidence.

Second, we believe that Mr. Green's analysis of what he considered to be the most significant *Georgia-Pacific* factors have also been excluded under the Court's rulings.

And third, we believe that under the standard set forth in the Court's ruling excluding Dr. Mangum, ePlus's expert, that Mr. Green's opinions must also be excluded.

First, with respect to the Lawson/IBM agreement, Mr.

Green's analysis is focused on the amounts that would be reasonable for ePlus and for Lawson to accept in a hypothetical negotiation. That is the foundation and centerpiece of his opinion. But the benchmark for Mr. Green's opinion about what this hypothetical negotiation would result in are the royalty rates in the excluded Lawson/IBM agreement.

Specifically, Mr. Green concludes that Lawson would have only accepted a range of about 600,000 to \$900,000 as the conclusion for his hypothetical negotiation by using, and he says, quote, the rates that Lawson actually pays to IBM for the use of its technology including software and the Websphere agreement of one percent and 3.25 percent. That's on page 22 of Mr. Green's report.

The Court, in ruling on ePlus's motion in limine number seven, has decided already that this Lawson/IBM agreement that Mr. Green relies upon is, quote, irrelevant and that any marginal relevance about the agreement is substantially outweighed by the risk of jury confusion and unfair prejudice, and, thus, is excluded by Federal Rule of Evidence 403.

The second point that I'd like to make is that Green's analysis of what he considers to be the most significant *Georgia-Pacific* factors has also been excluded.

Mr. Green opines about two *Georgia-Pacific* factors in particular that he stresses are, quote, the most significant.

First, Georgia-Pacific factor two, that's a factor that takes into account the rates that Lawson has paid for the use of other patents comparable to the patents-in-suit, and analyzing this figure, Mr. Green reviews ten different Lawson software and technology acquisition agreements, and he concludes, based upon his review of these agreements, that Lawson and ePlus would have agreed to a lump sum royalty structure. The Court has ruled that each one of those ten agreements Mr. Green relies upon is excluded from evidence.

The second factor which Mr. Green considers, quote, the most significant, is *Georgia-Pacific* factor number nine.

That's a factor that compares the utility and advantages of the patented technology versus older modes and older ways of accomplishing what's described in the patent.

Now, Mr. Green's analysis of this factor is based on his review of a reexamination filing. The Court has already ruled that the reexaminations shall not come into evidence at trial, and Mr. Green concludes, based on reviewing these reexamination filings, that the older ways of doing the procurement type of technology described in the patent were the same as what's described in the patent. In other words, the patented technology is, quote, in his opinion, not a significant improvement over older modes and devices.

And this is a basis for his opinion that the amount that the parties would have agreed to in their hypothetical

negotiation is lower than it otherwise would have been.

THE COURT: Isn't there an expert, some other expert that testifies to that that he's using as a basis for his opinion?

MR. STRAPP: No. He has said in his deposition testimony that the sole and exclusive basis for his opinion was his review of a reexamination filing drafted by Lawson's attorneys. The Court has ruled that his opinions about Georgia-Pacific factor nine are, therefore, not admissible in evidence.

The third point I'd like to make is that under the Court's ruling excluding Dr. Mangum --

THE COURT: Why can't he just use the other 13 factors?

MR. STRAPP: Well, Your Honor, his opinion is -- has two parts to it. First, he has an analysis of a hypothetical negotiation, and then he has a review of *Georgia-Pacific* factors. His hypothetical negotiation is now fatally flawed because it's based on royalty rates from an agreement that's been excluded.

His analysis of the *Georgia-Pacific* factors, it's true, produced several factors. He decides that certain of those are the most important and are critical to his analysis that the reasonable royalty would be a lump sum structure and that the amount that the parties would have agreed to would

have only been \$800,000, and the two factors, two of the factors that he considers the most significant are factors two and factors nine. Those are now inadmissible.

We believe that this undermines his opinion such that he would no longer be able to provide reliable expert testimony under Rule 702. He no longer has sufficient facts or data upon which to base his opinions.

The third point I'd like to make is that the Court has already excluded Dr. Mangum based, in part, on what the Court considered to be his shaky benchmark, the litigation agreement, the SAP and Ariba agreements. Well, compare Dr. Mangum, and contrast that with Mr. Green. Dr. Mangum, the Court has said, has a shaky benchmark. Mr. Green has no benchmark whatsoever. The Lawson/IBM agreement is no longer in evidence.

The second point, the Court said that Dr. Mangum's analysis of the *Georgia-Pacific* factors was speculative, and that was another reason that the Court excluded Dr. Mangum.

Well, again, compare and contrast Dr. Mangum with Mr. Green. Dr. Mangum's analysis of the *Georgia-Pacific* factors is speculative. Mr. Green can't even testify about what he considers to be the most significant *Georgia-Pacific* factors.

In sum, we believe that if Dr. Mangum has been excluded, Mr. Green must also be excluded.

I'd like to say --

1 THE COURT: For different reasons. 2 MR. STRAPP: I'm sorry, Your Honor. 3 THE COURT: But different reasons. 4 MR. STRAPP: Correct. The last point I'd like to 5 make is that if -- if Mr. Green is permitted to testify at 6 trial, we believe that Dr. Mangum should be allowed to offer 7 rebuttal testimony. Lawson agreed during the August 10th 8 hearing with Your Honor that the parties had an agreement that 9 experts could provide rebuttal opinions in deposition 10 testimony, and Dr. Mangum has provided rebuttal opinions to Mr. 11 Green's opinions in his deposition testimony. So to the extent 12 that --13 THE COURT: Your papers say they've agreed to this. Their papers don't say that. Why do your papers say they've 14 agreed to that when their papers say they don't? Can you help 15 16 me? 17 MR. STRAPP: Yes, Your Honor. 18 THE COURT: Or did I just misread their papers? 19 MR. STRAPP: What we were referring to in our papers, 20 was --21 THE COURT: Were you referring to what was said on that conference call? 22 23 MR. STRAPP: Exactly, Your Honor. Then it would have been a good idea to 24 THE COURT: 25 footnote that and say, based on that, no matter what they say

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

in their written papers now, that's what they said then. don't have to go back and root and read through something that makes me think that I just missed entirely a point that they were making or concession they were making. MR. STRAPP: Right. Your Honor --THE COURT: You won't do that anymore, will you? MR. STRAPP: Correct. THE COURT: That's the fundamental problem with most of the papers in this case. Both sides. MR. STRAPP: What we were referring to, as Your Honor suggests, is to the statement made during the August 10th hearing, and at page seven of that hearing, Your Honor asked Mr. McDonald, quote, Mr. McDonald, did you agree or not agree that the deposition would serve as a rebuttal report, that is, Mangum would have the opening, response would be by Green, and the deposition of Mangum would be a rebuttal report? Did you or did you not have that agreement? Mr. McDonald: We agreed, yes, Your Honor, that the deposition would be -- I would call really the surrebuttal, to be clear, because I would view Green, our damages expert, as the rebuttal witness. And then Mr. Mangum would have the chance to surrebut his report. That's what the agreement was. That's what we were referring to in our papers. THE COURT: All right. Thank you. MR. McDONALD: Morning, Your Honor. I have some

slides here. May I hand up a hard copy of the slides? 1 2 THE COURT: All right. 3 MR. McDONALD: If you go to slide 20, Your Honor, the 4 first tab, I think 20 is where this section regarding Mr. Green 5 begins. I'll address all three of the points raised by ePlus's counsel to show why Mr. Green's testimony should be allowed 6 7 here. 8 If you go to the next slide, number 21, I believe, 9 ePlus's briefing does not challenge Mr. Green's methodology as 10 we pointed out and ePlus, apparently, does not dispute. He did 11 take fundamentally different approaches to the issues from Mr. Mangum that avoided the pitfalls of Mr. Mangum's report. 12 13 One is he did come up with analytically sound benchmarks for determining the range of royalties --14 15 THE COURT: The IBM agreement is out, though. 16 that's the lynchpin of his analysis. How can he have a basis for his hypothetical opinion? 17 18 MR. McDONALD: Because there is another range of 19 benchmarks that he came up with based on ePlus's expected rate of return from their own documents that was --20 21 THE COURT: Where is it? 22 MR. McDONALD: If you go to Exhibit F. 23 Do you say anything about it in the text? 24 MR. McDONALD: Yes. 25 THE COURT: Where is it in the text?

```
1
               MR. McDONALD: At page 21. There's a section there,
 2
     section one, ePlus.
 3
               THE COURT: That is the starting point for ePlus, not
 4
     for Lawson.
 5
               MR. McDONALD:
                              That's right.
 6
               THE COURT: Their argument is that the way he framed
 7
     it was -- his analysis was that each one of them had a starting
 8
     point. ePlus had one, Lawson had one. Lawson's starting point
 9
     was the IBM agreement. It's out. There's nothing left.
10
     you've got nothing in juxtaposition to the ePlus, and so his
11
     fundamental premise for the negotiation, having been gutted, is
12
     gone, and that the rest that's left is unreliable. Why isn't
13
     that right?
14
               MR. McDONALD: Well, there is --
15
               THE COURT: You can't use ePlus's starting point.
16
     You can't convert what he said into using ePlus's starting
     point into Lawson's starting point.
17
18
               MR. McDONALD: Separately from --
19
               THE COURT: If you're going to do that, just quit,
20
     because I haven't any time for that.
21
               MR. McDONALD: I can show you in his report where he
22
     says --
23
               THE COURT: Show me.
24
               MR. McDONALD: At pages 40 to 41.
25
               THE COURT: Okay, now, where on 40?
```

MR. McDONALD: Where he talks about the range -THE COURT: Let me see the text. I'm through
listening to you all's arguments. I want to see it, because
I'm telling you what we have here is a situation in which every
time I go to check something, there's nothing there, and I'm
tired of it. We're through with it. You can make your point
and show me exactly where it appears.

MR. McDONALD: At the bottom of page 40, the very last sentence begins, "a lump sum royalty of almost \$800,000 is reasonable in comparison to other financial metrics."

Then at the top of page 41, there are three bullet points.

THE COURT: Wait a minute. Okay.

MR. McDONALD: Where he compares that metric to Lawson's actual license and maintenance revenues as a percentage is the first bullet point. He says it's about .6 percent based on Lawson's actual license and maintenance revenues since 2004.

The second bullet point, he says, that amounts to two percent of Lawson's operating profits from licenses maintenance revenues relating to procurement products.

Then the third point, it's 800,000 is the midpoint that ePlus would have sought from Lawson. Then he's got the second half of that sentence, and that's the part that you have said was inappropriate. It's consistent with the midpoint of

the present value of Lawson's range. So that's the part that's out.

But the prior two bullet points and the first half of that last one -- I'll focus on the first two, because the first two bullet points have to do with from the perspective of Lawson, would that \$800,000 figure be reasonable even if the IBM license or any of the other license agreements are not considered regardless of whether the Lawson range that Mr. Green developed is considered --

THE COURT: He didn't say that. He doesn't say that. That's what you're saying. He doesn't say that. He links them inextricably together, and one is the foundation and the mortar for his opinion, and it's like a three-cornered stool and one of them is gone. When you sit on it, the whole thing collapses.

MR. McDONALD: Well --

THE COURT: You can't make a silk purse out of a sow's ear.

MR. McDONALD: Well, if the situation -- and as I understand the evidence is there is no range for Lawson. ePlus has not pointed to any other range that Mr. Green or any other expert could use.

I don't think the law stands for the proposition that if there is no range that can be developed under the evidence from the licensee's perspective, you don't have -- you can't

analyze royalties, period.

THE COURT: I absolutely think that's correct, but that isn't what your man did. That's what you're trying to work out now. You are constrained by what your man said. Your man said something. He took the risk that what he was saying was wrong. He tried to convert, use a lump sum, tried to use something, and he knew that he had a risk in doing it, or you should have known that he had a risk in doing it.

He chose to run the risk. He built his house of cards. One of the pieces fell, and he doesn't have anything left. That's what they say. Why isn't that right? Don't tell me what you could have done under the law, because I agree there's lots of ways to do things. It's what he did that's the issue.

MR. McDONALD: I think literally what he said at pages 40 to 41, the \$800,000 figure was reasonable in comparison to three financial metrics. One of them, you've said, or half of one of them is out. I don't think he was saying, I have to rely on all three of those to find that figure reasonable from Lawson's perspective.

I think the first two bullet points are not dependent on the license-related range that he came up with as literally stated in his report. So that's how I would address or respond to that issue.

THE COURT: All right.

MR. McDONALD: I do think it satisfies the requirements that Mr. Green -- even if you throw the IBM license out, he did consider this from both sides, from the licensor and the licensee's side. I think that page 41 analysis shows that.

You got the charts -- or pages 30, 37, and 38, as well as charts, Exhibit E and J, also present the evidence from Lawson's perspective that would support the reasonableness of this lump sum royalty he came up with.

There's no dispute, I think, that the evidence would support that it's reasonable from the ePlus perspective, and I do think it's still helpful to the jury to present that evidence.

THE COURT: All right.

MR. McDONALD: Are there other questions that you have --

THE COURT: Anything else?

MR. McDONALD: Just that it's not a methodological flaw, Your Honor, that is in here. It's a fact issue with respect to the non-infringing alternatives. His testimony was he had looked at the prior art as described in the re-exams, but evidence will come in through the fact witnesses --

THE COURT: No, no, no. That's what he said. That's what he staked out. He didn't relate his opinion to anybody else's comments. He related it to the re-exam according to

them. Show me where he did not relate it to the re-exam. They showed me where he did. They may be mistaken.

MR. McDONALD: At page 32 of his report is where he talks about these alternatives, the older modes or devices.

That's Georgia-Pacific factor number nine. In that section, he makes it clear that he's --

THE COURT: Where are we talking about so I can see?

MR. McDONALD: Page 32 on Georgia-Pacific factor

number nine.

THE COURT: What text are we talking about?

MR. McDONALD: In the second paragraph there, you see he says, "I understand that the purported benefit of this patented technology is the integration of catalogs, requisition and purchasing functions. Each of these functions had occurred independently or in pairs in prior systems."

Then he goes -- continues to specify the aspects of those prior systems. The next paragraph, "I understand that there are numerous low-cost alternatives to the use of the patented technology." He's not relying here on the re-exams.

THE COURT: I thought that he said at the deposition he -- when asked about this comment, he said that he was relying on the re-exams for papers to reach -- to base those conclusions. Isn't that what the argument was, or did I misunderstand?

MR. McDONALD: He testified that he actually had

looked at the prior art descriptions and the reexamination papers. That's where he developed an understanding of that. But that was -- his report is not going to be based on him testifying about what the re-exams say.

He is saying, I understand this. This is what the expert can do, and, in fact, the prior ruling was that his admissibility on this point would be subject to laying a foundation for the prior art evidence to come in whether it's through fact witnesses or expert witnesses, and the Court already ruled on that.

THE COURT: Well, that's until I misunderstood what you all were trying to accomplish here in this and how you were approaching the issue.

MR. McDONALD: I think that was a reasonable way to decide that because he's a damages expert. He's not an expert on prior art and technology. It's appropriate for him to say, this is my understanding of the evidence that will come in, I'm not going to testify on that myself, but if that's the evidence, that would support my opinion.

THE COURT: He can't give that opinion. All right, anything else?

MR. McDONALD: No. Thank you.

THE COURT: He says that the factor number nine analysis is not based on the re-exams. As I understand your papers and your argument, you said that at Mr. Green's

deposition, he acknowledged that the *Georgia-Pacific* factor nine analysis appearing on page -- beginning on page 32, and I guess it's ending on what?

MR. STRAPP: Page 36.

THE COURT: 36 here was based on the reexamination papers only.

MR. STRAPP: Your Honor, I might have been mistaken, but I thought I heard Mr. McDonald say that the basis of Mr. Green's analysis was his review of what had been filed at the reexaminations.

I think what Mr. McDonald is suggesting is that Mr. Green should be permitted to get up at trial, and if the evidence has already come in through other means at trial, then say, oh, that evidence supported the opinion which I had gleaned from the reexamination filings upon first review, and we believe that would be inappropriate.

Under Rule 26, an expert is required to disclose all the bases for his expert opinion, and to the extent that Mr. Green's only basis, when he filed, when he served this expert report upon ePlus, was a reexamination filing, and the Court has ruled, in granting ePlus's motion in limine number seven, that his opinions about this subject are inadmissible, that we don't think Mr. Green should be permitted to testify about this at trial. This is one of several problems that we've identified with his expert report.

THE COURT: All right. Thank you. The motion to exclude Mr. Green's report will be granted. I have been through all of the papers again and his report and the earlier information, and the points that ePlus makes are well-taken.

I will recount for purposes of analysis the bases of the law as it was developed in consequence of the *Daubert* and *Kumho* decisions, and as it appeared subsequent to the 1993 revisions to the Federal Rules of Civil Procedure, and we will begin with the Federal Rules of Civil Procedure.

For some reason there seems to be a notion that these rules don't mean what they say, but they do. Rule 26(a)(2), disclosure of expert testimony, says, "unless otherwise stipulated or ordered by the Court, the disclosure," disclosure of experts, and it refers back to rule A, capital A of sub (2) which says, "In addition to the disclosures required by Rule 26(a)(1), a party must disclose to the other parties the identity of any witness it may use at trial to present evidence under Federal Rule of Evidence 702, 703, or 705."

So that "disclose must be accompanied by a written report, prepared and signed by the witness, if the witness is one retained or specially employed to provide expert testimony in the case...the report must contain," and then it sets forth a number of things that the report must contain. The facts or data considered by the expert in forming the opinions, the complete statement of all the opinions he will express and the

basis and reasons for those opinions, and then it goes into the exhibits that will be used to summarize or support them, the qualifications of the witness, other cases testified to, statement of compensation.

Those requirements, particularly Roman (i), (ii), and (iii), are there for a very good reason, and the reason was this: If you will look at the reports of the committee and all the background literature that prompted this change, we had a situation obtaining before 1993 in which experts would give some kind of report. The other side would give a report. There would be depositions taken, and the depositions often reflected something entirely different than what was in the report, but not always.

And it even gravitated to the point that the witnesses would, at trial, either in direct or rebuttal, come up with theories and concepts that were roughly related to what they had said in the beginning, but the reasoning was all wrong, all different, all skewed.

In those days, the way one discovered expert testimony was to ask interrogatories, interrogatories that are permitted by the rule today, they are still permitted, but the committee said, stop that nonsense. The expert must put what he is going to say in his or her report, and they must state the complete opinion and the basis and the reasons therefor, the facts they considered in forming the opinion, not just the

ones relied on.

Now, I will tell you I'm fully aware that there is afoot a proposal in the federal rules committee to change the word "considered" to "relied on," but that isn't what this says. And my guess is the rule will be changed, but that's not the rule we have here now.

And the reason for all that was to stop what I call the evolving and revolving opinions of experts. That process made an utter mockery of the evidentiary rules and trials and the system. So this concept was designed, this rule was designed to bring reason back into the system, and if you don't live by that rule, you die. That's what's important to remember.

In 1993, Daubert was decided. Daubert was decided in context of an attack upon a decision -- or focused on the issue whether the old Frye rules that had been in effect since 1920-something, were of general acceptance in the scientific community, was the guidepost for the admission of expert opinions.

Once again, there's historical background to this.

This is the first case in the Supreme Court to blast junk science and to say, judges of the federal courts, stop it.

Judges had gotten into the habit of allowing experts to testify to anything without exercising much control at all over whether there was any rhyme, reason, method to the expert's opinion.

They just didn't go to the trouble of doing it. And if you had an eminence about you or your résumé or you testified you were an expert or you had testified in a number of cases, then the courts tended, in most places, to let the opinions in, and the Supreme Court in Daubert announced that this is stopping, and here's what you're going to do. You've got a rule, you have a gatekeeping function, district courts, and it is your job to keep out expert junk, and junk can be true junk, concocted junk, or junk can be unsound methodology that offends the basic rules that let us let evidence in.

Rule 702, which is predicated upon concepts of relevance an reliability that are described in the *Daubert* opinion, says that we are not to allow speculation and unsupported speculation, and then it goes on to describe how one assesses method. The lynchpin of relevance, of course, is the requirement in Rule 702 that the evidence or testimony will assist the trier of fact to understand the evidence or to determine the fact in issue.

There is another component of relevance that is critically important when doing the case-by-case analysis required by the *Daubert* gatekeeping function, and that is the concept of fit. Fit is a function or an aspect of relevance, and that is whether the expert testimony proffered in the case is sufficiently tied to the facts of the case that it will aid, i.e. -- remember, aiding the jury is a relevance component. It

will aid the jury in resolving a factual dispute. One of the two predicates of relevance is understanding the evidence. The other is deciding a fact in issue.

So if the evidence doesn't fit, it's not relevant either. Then the reliability component focuses upon the methodology, and *Daubert* says the gatekeeping function is to be conducted in perspective of both of the concepts embodied in Rule 702, relevance and reliability. Subsequently, Rule 702 was amended to incorporate these basic concepts in its text.

The rule also says, that is *Daubert* also says that other rules of evidence have to be considered when deciding expert issues, and, notably, among them is Rule 403. It has a particular significance in the case of expert reports because experts can -- reports can create confusion and delay and create unfair prejudice if not tethered to the relevance requirements and the reality requirements.

Kumho Tire Company v. Carmichael in 1999 said that the concepts of Daubert, including the gatekeeping function, are relevant to all kinds of expert testimony, whether scientific, technical, information by training, or information by experience as well, and it held as well that some of the formulations used to test scientific evidence had equal applicability or analogous applicability on a case-by-case basis in testing other kinds of expert opinions.

But both cases taken together direct that judges not

allow speculation and that method is extremely important, and the cases in our circuit have continued to go that way. The cases in the federal circuit have gone that way.

Against that background, we consider the motion to exclude the Green report. The Green report has, as a fundamental premise, the Lawson/IBM agreement which has been excluded by virtue of the ruling on motion in limine number seven. That document and agreement formed the lynchpin of the hypothetical negotiation analysis structured by Mr. Green in his report. He chose to do his report two ways. One was where Lawson would start from, one was where ePlus would start from in the hypothetical negotiation.

He chose to use the IBM/Lawson agreement as the lynchpin of the starting point or the starting point for Lawson, and he then went on and, as counsel points out, he talks about lump sum royalty, that he picked that range of 600 to 800 million out of the IBM agreement construct, and says so, and then he says on page 40 and 41 that a lump sum royalty of, at most, 800,000 is reasonable in comparison to other financial metrics, and he puts three in there, and they are correlative, constituent elements of his analysis if you read the whole section upon which he predicates his hypothetical negotiation, and when the IBM agreement was excluded, the predicate for his opinion was eliminated.

As such, the opinion and his opinion and his report

no longer have any fit as used in *Daubert* and are of marginal -- what remains is of marginal relevance, although of some relevance, but it is, in fact, analogous to a three-legged stool, one leg of which has been destroyed. You can't sit on one of those stools, and that's exactly what his hypothetical negotiation amounts to.

In addition to that, two of the most significant, what he regarded as the most significant factors in the Georgia-Pacific analysis, factor two and factor nine, were eliminated by virtue of other motions in limine. The rates for ten -- he used the rates for ten or so comparable patents in Georgia-Pacific two to arrive at his conclusion of a lump sum royalty, and all of those are gone.

In Georgia-Pacific nine, he bases his analysis upon the reexamination proceedings which have been excluded as well, and he testified at his deposition that all the information came from the ex parte reexamination request for the '516 patent. And he was asked, "So as of the date you filed your report, the basis, sole basis for your opinion concerning non-infringing alternatives was your review of the reexamination files.

Answer: Fundamentally yeah. I had gone through and tried to understand some other information regarding some of these companies and what they were doing, but, yeah, fundamentally it was the reexamination files that I was aware

of."

Those are out, and so two of the most significant components of his opinion on the *Georgia-Pacific* factors are out.

Even if -- so what's left is this: He's got his most important factors in his analysis out. The rest then becomes speculative and contains no fit. And the relevance is marginal, and the reliability of an analysis that says, I can render the same opinion if you take the premise of one part of it and the guts of another part of it out, simply has no place in a Daubert analysis, and that's precisely what Mr. Green has done.

Taken as a whole, the remaining method for his bootstrap opinion that counsel would have him offer absent the stricken parts of it is of no moment, and in addition to that, that isn't the opinion he really offered in the first place in compliance or in an effort to comply with Rule 26(a)(2).

So, that motion will be granted for those reasons. I may issue an opinion. It depends upon how much time I have left after dealing with all of the papers that you all have.

Lawson's motion to preclude ePlus from presenting any new damages theories or seeking damages at trial, I think I'd just like to hear from ePlus first on this because I don't see in the papers where your disclosures or your discovery responses allow you to go anywhere other than with the Mangum

report which is out.

I think as a general proposition, it is clearly the case that a case can be presented under the law on the issue of damages and reasonable royalty without an expert opinion. I don't think there's any law that I know of that requires an expert, but that isn't the issue as I see it here.

The issue is whether, with Mangum gone, ePlus made, can be shown to have made any compliance with Rule 26(a)'s damage calculation compliance or the response to the interrogatories that Lawson asked on the issue. Therefore, the question is whether as to this case on this record there exists some predicate that would allow the introduction of any evidence that was presaged by what it must be presaged by and that is disclosure as to your damages, not just your theory but your method of computation and your actual computation and answers to interrogatories about those damages.

So I'll hear from ePlus on that at this time. And I'd like to see exactly what parts of the record contain that information so I can understand it.

MR. MERRITT: Good morning, Your Honor.

THE COURT: Morning.

MR. MERRITT: Craig Merritt for ePlus. I do have a low-tech handout, if I might hand it up.

THE COURT: I'm a low-tech reader.

MR. MERRITT: I'm a low-tech reader myself. The

other thing, Your Honor, as I address this that might be helpful for you to have in front of you, if you don't already have it, is Lawson's opening brief.

THE COURT: I have it.

MR. MERRITT: Judge, what I would like to do in answering your very pointed and very clear question is to frame this for a moment by talking about the legal standards and the rules -- I think the rules do matter -- and then talk specifically about the three nondisclosures that Lawson lays at the feet of ePlus and talk about each of those three separately and distinctly.

First, on the question of standards, I understand this morning that we're proceeding under Rule 37(c), and Lawson cites 37(c)(1) at page four of its brief. I would be remiss before talking about the discovery rules if I didn't state that this is an issue-dispositive motion. This motion takes damages out of this case.

Now, typically Lawson would be moving under Rule 56 or at trial under Rule 50, and not deciding this, not taking damages out under one of those rules, really has two consequences for ePlus that we believe should be approached with some caution.

First of all, in this court, if Lawson takes out damages under Rule 37 as opposed to Rule 56, Lawson has never really had to state why the evidence doesn't support a jury

finding of damages. ePlus doesn't have to respond by marshaling the evidence. ePlus doesn't get the benefit of inferences drawn in its favor that it would get as a nonmoving party under Rule 56.

The other thing that happens in deciding this under Rule 37 rather than Rule 56, the deadline for which passed sometime ago, is that ePlus loses a standard of appellate review that's much more favorable, frankly. Should the Court believe this doesn't go to the jury, anything the Court does would be decided under an abuse-of-discretion standard under Rule 37 as opposed to the less deferential *de novo* standard under Rule 56.

I say that simply as a cautionary note that if this is a form of disguised dispositive damages motion, we need to think about whether this is the way this result should be accomplished on the particular record of this case.

Now, at page four of Lawson's opening brief, Lawson sets out Rule 37(c)(1), and that is the source of the remedy they are seeking this morning, and it says that if a party fails to provide information or identify a witness as required by Rule 26(a) or 26(e), the party is not allowed to use the information or witness to supply evidence on a motion at a hearing or at trial unless the failure was substantially justified or is harmless.

I'd like to focus on the phrase "as required by

Rule 26(a) or Rule 26(e)" for a moment. Rule 26(a)(1)(iii) is cited at page two of Lawson's brief, at the very top of page two. I won't read it in its entirety, but I'd like to point out a couple of aspects of it. It does require as part of the initial disclosure that the party bearing the burden on a claim provide a computation of its damages, but then it goes on to say this: "Must also make available for inspection and copying as under Rule 34 the documents or other evidentiary material, unless privileged or protected from disclosure, on which each computation is based."

That passage presupposes the timely availability of the evidentiary material. In other words, the duty that that statute imposes is clear. The question in this case that I want to explore with the Court for a few minutes is when was ePlus first in a position to discharge that duty. We acknowledge the legal duty. 26(e), which is not cited in Lawson's brief but is actually the failure that we're charged with, the failure to timely supplement, under 26(e)(1), a party who has made a disclosure under 26(a) or a party who has responded to any other discovery question, and I am paraphrasing, not reading literally, must supplement or correct its disclosure response.

(e)(1)(A) says the following. This is subsection capital A. "In a timely manner if the party learns that in some material respect the disclosure or response is incomplete

or incorrect," and then there's a phrase that Lawson never mentions in its brief, "and if the additional or corrective information has not otherwise been made known to the other parties during the discovery process or in writing."

The rules do matter, and reading them as a whole does matter. Now, with those rules read as a whole, I'd like to try to respond to the three things Lawson has charged us with in its motion.

Supposedly ePlus has failed to disclose three distinct things: Number one is its theory of damages. Number two is information regarding the royalty base, and number three is information regarding the royalty rate, and we know that because it comes right out of the first two sentences of the first page of the brief they filed on this. Those are the three things with which we are charged; nothing regarding damages contentions or theories, nothing about a royalty rate, nothing about a royalty base.

I'd like to look at each of those three things and see what the state of the record is on those at this point in answer to Your Honor's question.

First on theory of damages, theory of damages, and I take it from -- I'm inferring from some of the Court's comments before I stood up that this may be of less concern to the Court, but I want to address it anyway.

At page two of Lawson's own brief, they have the

initial disclosure that was made by ePlus. It says, in no uncertain terms, that ePlus will seek at least a reasonable royalty. The response to interrogatory number 17 that's also cited says that ePlus will seek no less than a reasonable royalty. That was disclosed August 11, 2009, and October 12, 2009. We're pushing on -- well, we're past the one-year anniversary of the time ePlus said it was going to seek no less than a reasonable royalty.

It's clear from the record that the *Georgia-Pacific* factors, which have been the law controlling reasonable royalty since 1970, are very well-known to the patent bar, and you have some of the finest patent practitioners in the country in this court. I do not include myself among them, but I'm happy to be here with them, and it's very interesting.

If you look at the exhibit that I've handed up to you in the book, which is -- I'm sorry, Your Honor. It's not in the book. This is an exhibit attached to our opposition brief. I apologize. It is Exhibit M to our opposition brief.

Exhibit M is a third amended notice of deposition that Lawson sent to ePlus in December of 2009. If you work your way back in the notice to page six, after the obligatory endless definitions that we all seem to have to put at the front of these things, you'll get to the list of topics to be covered.

As early as December 2009, Lawson was taking 30(b)(6)

depositions of ePlus witnesses on a number of topics, many of which included the *Georgia-Pacific* factors. Number one goes to the competition factor, two number goes to competition. Number eight goes to licensing practices. You can go through this, and I won't go through it step by step. There are also topics that aim at non-*Georgia-Pacific* factors.

The point is the idea that the theory of this case and the reasonable royalty as the basis for discovery was not disclosed is simply untenable based on the discovery record and the parties' own conduct in thoroughly discovering all of the Georgia-Pacific factors.

THE COURT: Did they take a 30(b)(6) witness of ePlus on the topic of reasonable royalty?

MR. MERRITT: They took --

THE COURT: Or damages.

MR. MERRITT: They took the 30(b)(6) deposition of Ken Farber in December of 2009 who is an ePlus executive, and they went through a number of these *Georgia-Pacific* factors that he was presented on, to testify on. He was asked, for example, about the prior licensing activities, all of the things that go to the determination of a reasonable royalty.

I don't believe he was asked what he believed a reasonable royalty would be, and they probably wouldn't have wanted to hear the answer anyway, and he wasn't an expert, but the underlying facts, the <code>Georgia-Pacific-related</code> facts were

```
fully explored with that witness.
 2
               THE COURT: Which Georgia-Pacific factor is covered
 3
     by which of the topics?
 4
               MR. MERRITT: Well, I'll give you the ones I was able
 5
     to pull up last night looking at this just quickly. Topic one
     and topic two on this notice --
 6
 7
               THE COURT: Are on Georgia-Pacific what?
 8
               MR. MERRITT: Factor number five.
 9
               THE COURT: What else?
10
               MR. MERRITT: Number eight would go to factors three
11
     and four.
12
               THE COURT: Isn't six some Georgia-Pacific --
13
               MR. MERRITT: Yes, it is. I passed over it by
     mistake.
14
15
               THE COURT: Which one is that one?
               MR. MERRITT: Factor number four.
16
17
               THE COURT: Any others?
18
               MR. MERRITT: Number nine would go to factor number
19
     five. Number 23, page nine, would go to factor number eight.
20
     I won't represent that there are others, but I will represent
     it was getting pretty late last night when I looked at this,
21
     and I may have missed a few, but those are the ones that
22
23
     immediately came to mind just looking at this.
               The point of this is that from the standpoint of the
24
25
     disclosure of the theory of damages -- let's set aside the
```

calculation, the rates, the underlying facts --2 THE COURT: I don't think there's any dispute over 3 the fact the theory was disclosed. 4 MR. MERRITT: Well, the only reason I even respond to 5 it --6 THE COURT: Is because they made some statement in 7 one of the briefs that you don't even know what your new theory 8 is. 9 MR. MERRITT: Absolutely. It's clearly the same --10 THE COURT: I understand that. 11 MR. MERRITT: The other thing is, just so, again, the 12 record is clear on this, with regard to theory, there's a 13 statement in Lawson's reply brief, their memorandum, at page two, that this Court's ruling on Dr. Mangum was a ruling on 14 ePlus's theory of damages. We don't understand --15 16 THE COURT: So don't argue that. 17 MR. MERRITT: Your Honor, I will address then the royalty base disclosures next. 18 19 THE COURT: Where is the royalty base disclosed in 20 answer to any disclosure or any interrogatory answer or 21 otherwise in discovery? 22 MR. MERRITT: Let me take that on. First of all, let's remember what royalty base is. The royalty base is the 23 revenues that Lawson attains or garners by selling the accused 24 products that are related to its infringing activities. 25

1 Now, it's very interesting to remember, and memory, for all of us, is short on this --2 3 THE COURT: Memory is what? 4 MR. MERRITT: Memory is short on some of these 5 things, it is for me, but looking back at this, the question is, assuming there's a duty to disclose, and there is, clearly, 6 7 under 26(e), when could ePlus first have discharged that duty 8 given the development of discovery and the facts in this case? 9 THE COURT: The answer to that, Mr. Merritt, is ePlus could have discovered it and had it basically ready by the time 10 11 they filed the lawsuit. It had filed lawsuits all over the country, litigated the issue twice. 12 13 You can get sales revenues from a number of different places, and you can basically put it together, not with the 14 15 precision that Mangum did, but they could have done it before they filed the lawsuit, couldn't they? 16 17 MR. MERRITT: No, sir. 18 THE COURT: No? 19 MR. MERRITT: No, sir. THE COURT: Isn't Lawson a public company? 20 21 MR. MERRITT: Lawson is a public company. THE COURT: Doesn't it file these financial records 22 and audited financials, it has revenues and everything in it? 23 MR. MERRITT: It absolutely files a 10-K. 24 25 THE COURT: But it doesn't have it by product?

MR. MERRITT: It doesn't break down to the level that you could fairly say that this is the accused revenue stream. It would be sheer speculation to do that, and this actually leads to the point I just want to take a moment to revisit. If we look again at Lawson's opening brief at page two, they begin sort of a timeline of the various disclosures that were made.

THE COURT: Is your theory here that these disclosures were made, they were just made in -- they weren't made in Rule 26(a) disclosures, they weren't made in the interrogatory answer, that is the royalty base, but they were made in Mangum's report so the factual data is there? Is that the point, it's otherwise made available in the discovery?

MR. MERRITT: That is the bottom line, and the point I wanted to connect that with, so that the Court would not feel that there was any lack of diligence here, you may recall some of the motion practice we had as late as March and April of last year trying to extract revenue data from Lawson.

The revenue data that was disclosed on May 3rd -Mangum's report, in that regard, truly is just a summary of
numbers. It requires no opinion to add up numbers. That was
disclosed. That was disclosed on May 3rd based on information
that was being received as late as April 30th. And, in fact,
as you'll see, and you don't have the entire report here, but
in the handout that I handed up to you behind tab L, first page
or two of Mangum's report at page -- we're behind tab L in what

I've handed up. Page three of that initial report, Dr. Mangum had to drop a footnote to part roman numeral (iii) that says, "I understand Lawson produced additional financial information to ePlus on Friday, April 30th. I've not yet had an opportunity to review this new information. Accordingly, I'll supplement and update this report at a later date as appropriate to reflect the new information."

THE COURT: Did he?

MR. MERRITT: He did. He did it behind tab M. There is a May 14th supplementation based on additional information received from Lawson, and behind tab N, as late as June 13th, a second supplementation based on the continuing receipt of licensing and maintenance information from Lawson.

My only point on this is -- you have already cut to the chase. Yes, we do believe that factually the disclosure of the revenue was made in the Mangum report which was incorporated by reference into the supplemental interrogatory response. We understand --

THE COURT: Where did the Lawson revenue base come from that is in the report?

MR. MERRITT: The Lawson revenue base came from -THE COURT: Those figures. Sorry, I didn't ask the
right question. Where did the figures come from?

MR. MERRITT: The figures were produced by Lawson as a series of spreadsheets that continued to go through various

iterations through the spring of 2010 and finally landed in a reasonably usable form a few days before the expert report had to be submitted. So assuming --

THE COURT: Did Mangum manipulate any of the data that was provided by Lawson as a revenue base, as revenue from the accused products in order to get to the figures that are shown as the royalty base in Mangum's report, or did he just take those figures and put them in there saying, this is where I got them?

MR. MERRITT: I believe it's the latter. What he did, to the best of my understanding, is that Lawson provided spreadsheets that had revenues associated with certain stock-keeping units, or SKUs, that, we believe, under our version of the evidence, and there's an evidentiary dispute on this, are associated with infringing activity.

So he simply took the SKUs and added up the numbers that were provided by Lawson. It's a summary. It's like a Rule 1006 summary of an underlying chart. That's the revenue information.

Now, there are some questions that have been raised by Lawson, one by a motion in limine on the SKU.

THE COURT: I have that one still pending, I think, don't I?

MR. MERRITT: Yes, sir. Another that keeps being floated indirectly, we don't understand why it keeps being

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

floated but was never the subject of summary judgment if Lawson believes there's a legal basis for it as to the inclusion of maintenance and services revenues, but in terms of just what Mangum did, he took the SKUs that we allege are associated with infringing activity, he took the information provided by Lawson and added it up. THE COURT: And that information came off those spreadsheets. MR. MERRITT: Yes, sir. THE COURT: So he had to take the information about accused product A and add it to information about accused product B, et cetera, so he did the math figures? MR. MERRITT: Yes, sir. THE COURT: Is that the manipulation he did? MR. MERRITT: Yes, sir. In sum and substance, that is what I understand he did. THE COURT: And in no other place in the record is that disclosed; is that correct? MR. MERRITT: I think that's correct. THE COURT: But the root of it all came from Lawson in the first place. MR. MERRITT: Lawson's own information. THE COURT: He added it together and did a mathematical calculation to come up with what you would like to present. In essence, what I'm asking you to do here today is,

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

what are you going to prove? Let me hear it. Let me see whether or not it did get disclosed. So you're going to offer the proof of these figures. How are you going to offer them? How are you going to prove that? MR. MERRITT: Lawson has a witness who we could call adversely. THE COURT: You're going to call a Lawson witness and say --MR. MERRITT: The Lawson witness, the witness who provided the underlying charts. THE COURT: You've deposed that witness, have you? MR. MERRITT: That witness has been deposed. THE COURT: And they were in attendance at the deposition. MR. MERRITT: Yes, sir. THE COURT: So that information is also available, not only to them but to the deposition of their witness and the mathematical results produced by Mangum. MR. MERRITT: Yes, sir. That's all as available at this point to Lawson's counsel as it is to us and has been since the deposition was taken and the documents were produced. So if the test is whether the supplementation to interrogatory number 17 should be the place where that is captured, then we lose. If the test is, as we believe it is under Rule 26(e), whether this has been fairly disclosed in the discovery process, we don't believe there's a basis for Lawson's motion on that.

THE COURT: The other part that occurs to me is that it looks to me like your answers to interrogatories used

Mangum's report as a supplement to interrogatory number 17.

MR. MERRITT: It's a written disclosure. I suppose we could have taken and made a Xerox copy and put it under 17.

THE COURT: No, no, but your interrogatory answer says, we're getting experts ready to do this now, and then he delivered the report. I'm not sure that's adequate, but nobody complained about it at the time.

MR. MERRITT: Nobody complained about it, and, honestly, I don't know, given the timeline of revenue information that was being produced, what could have been done more quickly. With an expert deadline looming on May 3rd, obviously, you work towards that. You're still getting information in the final days of April.

I suppose if someone with perfect 20/20 hindsight had wanted to do something more with the interrogatory response other than incorporate Mangum, then I'll take the fall for not advising my client to have done that.

THE COURT: Well, I think this: Just from reading all the papers, it seems to me as if the royalty base raw figures were disclosed and known to Lawson from their own information, but the real problem in the case is what about the

rate. That's where the rub is insofar as I can tell. I may be wrong about it, and I think that's really what they're going to testify -- I mean what their principal complaint is, and to me, it sounds like a pretty good one. So where is the royalty rate disclosed other than Mangum?

MR. MERRITT: Let me take that one on. First of all, the only rate that has been disclosed by ePlus in this case is in the Mangum report. There is no dispute about that. And we're not going to try to characterize anything else in the record as a disclosure of a rate because there has not been one.

As Your Honor knows, on August 10th, the Court opined that Dr. Mangum's opinion was going to be excluded, and it's out, and we understand that it's out. What ePlus proposes to do, and we believe the federal circuit law permits it -- in fact, we believe that in the *Dow Chemical* case the federal circuit found it to be error when a district court did not permit it -- would be to present evidence to the jury on as many of the *Georgia-Pacific* factors as the record will support and let the jury determine a reasonable royalty from those data points.

And we believe --

THE COURT: I understand what you are saying in general, but what actually are you talking about presenting? I think I understand the concept, and I think Dow Chemical is

correct that -- I mean you cite *Dow Chemical* correctly that that is a mode that is permissible of sorts. I'm not sure it's exactly -- I agree with everything you said.

MR. MERRITT: Understood. Judge, just by way of overview, all of these, by the way, are witnesses whose depositions have been taken, many of whom were 30(b)(6) representatives of their own companies. So these are not people on the fringe somewhere on the fly. Mr. Farber of ePlus can talk about licensing history.

THE COURT: What's he going to say?

MR. MERRITT: Well, we understand there's a question about settlement. We think the way to do that is to have a witness put in the terms and conditions of prior licenses on these patents without making reference to the fact that they were arrived at by virtue of litigation settlement.

THE COURT: I thought I held you couldn't do that.

MR. MERRITT: Your Honor, the only motion that there's been on that was Lawson's motion in limine number one. The Court determined, after its ruling on Mangum, that that had been mooted. The effect of mooting that is unknown, but it's certainly not been stated in an order of the Court that that is excluded --

THE COURT: It may not be moot any longer. That's another consequence.

MR. MERRITT: We understand that, but as the record

currently stands --

THE COURT: You said you put in the license terms but don't say it came in the settlement.

MR. MERRITT: That's correct. A district court in Texas has actually permitted that, and I'm sorry I don't have the case off the top of my head.

THE COURT: Was it an Eastern District of Texas?

MR. MERRITT: I believe it is, Judge.

THE COURT: The Eastern District of Texas is getting like what used to be the intermediate Missouri appellate court when I was in law school. If you wanted a decision on any issue, no matter what side it was, go to the Missouri appellate court, and you could find a case on it.

MR. MERRITT: Judge, they used to tell us that about California law, too. Taking California law in a Virginia state court was always a thrill-seeking exercise.

THE COURT: At one time, you could go to Virginia and find from the Supreme Court of Virginia any fact scenario on contributory negligence or what constituted the violation of the crossing law at railroads, but that's pretty much ended now.

MR. MERRITT: Judge, given the fact I'm still actively in practice, I'd rather not comment on that. I have my own thoughts, but I think I'll keep them to myself.

THE COURT: I'm saying they moved away from that.

All right, so he's going to testify about the prior license terms in what? What are they, SAP --

MR. MERRITT: Ariba, SAP, Perfect Commerce, SciQuest, and Verian, and that takes away, by the way, some of the concerns Your Honor had about selectivity among these on the part of Dr. Mangum, although we respectfully, of course, object to the Court's ruling.

THE COURT: You don't have to keep saying that. I know you object to it. I think if the federal circuit can't get that, they've got some real troubles. So you've objected and preserved the record. SAP, Ariba, SciQuest.

MR. MERRITT: Perfect Commerce and Verian,

V-e-r-i-a-n. The terms and conditions of those agreements

involve these patents-in-suit. Now, just as an aside, this is

sort of a thought experiment I've been trying to do and I can't

get a good answer to it, but it's an interesting one.

What happens in the first case? What happens in a case where Mr. Carr is a patentee, and he has one competitor, Mr. McDonald. He's just gotten his new patent, and he believes Mr. McDonald is infringing, and he sues him, and he goes into court, and there is no licensing history. He's never licensed it, he's never sued anybody.

THE COURT: You take licenses from comparable technologies or products, don't you, in the field? Isn't that what the rule is?

MR. MERRITT: If you can find them, if they're not like these IBM licenses were in this case or whatever, but it raises a very interesting question, and I just raise it because if there is information in licenses on these patents that are data points that we can give to the jury without the prejudice of saying, hey, guess what, these folks had a similar defendant in here and had a nice day, that's the real prejudice.

THE COURT: That, however, is another whole issue in connection with that that was raised in respect of their motion in limine number one which I had held was moot in view of the other one, and that is whether they are reliable or not without regard to the 403 type analysis, are they reliable because — what is it — Rude v. Westcott and other cases, and then there is one or two federal circuit cases that say, well, you can draw a distinction under certain circumstances where there's been an actual verdict and a reasonable royalty rate arrived at and use that as a factor, but that isn't what happened in any of these. There was a lump sum in these, wasn't there?

THE COURT: One of them had a running royalty of five percent after 15 million in sales or something like that, I believe.

MR. MERRITT: Yes, sir, although I do believe --

MR. MERRITT: Yes, sir.

THE COURT: Was that SAP or Ariba?

MR. MERRITT: I believe it was neither SAP nor Ariba,

1 as I recall. It was one of the other three. 2 All right. THE COURT: 3 MR. MERRITT: In any event, we know that's not been 4 decided, at least as a matter of record by the Court, and we'd like to have a discussion of that if one is available. 5 THE COURT: What else? Farber. 6 7 MR. MERRITT: Farber can talk about factor three to 8 the extent he can talk about licensing terms; factor four, 9 license or established policy; factor five, the commercial relationship between these two parties can be addressed by a 10 11 number of witnesses. Mr. Farber, and at least three witnesses we could call adversely from Lawson. Mr. Lohkamp. 12 13 THE COURT: Is there any dispute they are 14 competitors? 15 MR. MERRITT: I don't believe so. THE COURT: So that's three, four, and five. 16 17 MR. MERRITT: Factor six, the effect of selling the patented specialty and promoting sales of other products, Mr. 18 19 Christopherson and Mr. Lohkamp could be called adversely from 20 Lawson on that. Again, these are all people who have given depositions and have talked about these things, so, you know, 21 22 people know what issues they are able to speak to. 23 Factor seven, the duration of the patent and the term of the license, that, of course, the duration of the patent 24 would be evident from the face of each of the patents 25

themselves, whatever witness introduces those.

Factor eight, establish profitability of the products made under the patent, commercial success and current popularity, we have at least four witnesses from Lawson who've testified to that; Christopherson, Lohkamp.

THE COURT: What factor is it?

MR. MERRITT: Factor eight.

THE COURT: What is it? What are they going to say?

MR. MERRITT: Establish profitability of the products made under the patent. These witnesses have been asked about Lawson's 10-Ks, about various Excel charts that have been provided by Lawson. They've been asked about Lawson business forecasts that have been produced. All of these things go to this factor.

Factor nine, the utility and advantages of the patent property over old modes and devices, there's expert testimony on that from Dr. Weaver and Mr. Hilliard that's still good testimony and in evidence.

Factor ten, the nature of the patented invention, the character of the commercial embodiment, the benefit to those who have used the invention, there are witnesses from both parties who can speak to that including Farber, Frank, Oliver, Lohkamp. There are press releases and all sorts of materials that have been produced that go to that factor that these witnesses can be shown.

Factor 11 is the extent to which the infringer has made use of the invention and the value of the use. We have at least four witnesses from Lawson who can speak to that as adverse witnesses in our case.

THE COURT: How are you going to figure the value of the use? How are you going to do that?

MR. MERRITT: Well, we know what the revenues are.

We know what their gross profitability is on a range of products. It's been an interesting thing in this case because Lawson takes the position that you can't determine the profitability of the accused products, that they have no means of doing that.

THE COURT: I bet you if the president of the company wanted it, they could get it.

MR. MERRITT: Let me show you something. It's fascinating.

THE COURT: Although that's somewhat like saying everybody knows the Prussians kept the marching orders from the Franco-Prussian War, so I better maybe not give that line.

MR. MERRITT: Judge, if you will look at the handout that I gave you behind tab K, the one that I handed up when I first stood up in the little binder, tab K, you have here an April 21st deposition of Kenneth White who was a 30(b)(6) witness on, among other things, financial matters.

The first thing you see -- second page is actually

page 24 of his deposition transcript, and there's a remarkable passage that starts at line 15. "If Harry Debes, the CEO of Lawson, walked into your office one day and asked you whether the S3 supply chain management suite was profitable, how would you answer his question?"

The question is objected to.

"Answer: What I'd probably do is I would -- I'd tell him, no, we don't have the ability to do profit on a product-by-product basis.

Question: So it's your testimony that if the CEO or CFO of Lawson approached you to understand whether the S3 supply chain management suite was profitable, you would not be able to answer that question?" Ms. Hughey objects. Then there's an answer.

"Again, to answer your question, um, based on what I would explain to Harry or to Stefan, I would say, Stefan and Harry, I have revenues by product, but our costs are gathered on functional, geographical, or business-unit basis. I can't necessarily get you a product by product profitability.

Question: How does Lawson make business decisions about whether to continue manufacturing and selling products if it has no ability to track the profitability of its products?

Answer: I don't know that answer."

Now, given that --

THE COURT: Don't many companies just allocate costs

on an allocated basis across the board? MR. MERRITT: They may, but the only point --2 3 Did anybody ask him if that's what they THE COURT: 4 did? 5 MR. MERRITT: Well, they say they allocate them but not on a product-by-product basis, so, apparently, you don't 6 7 know if a particular product is profitable or not. My point on 8 that is in terms of evidence we would present, we have evidence 9 of the revenue stream that's generated by the product. We have 10 evidence of the general gross profitability across a range of products. We don't have granular profitability at the 11 product-by-product level because the testimony Lawson's 12 13 30(b)(6) witnesses have given us is that's not available and can't be done. So to that extent, we're a little bit hamstrung 14 on that point. But, again, just --15 16 THE COURT: Just curious why you didn't go take the deposition of the chief executive officer and ask him why -- if 17 18 that was true, why he put up with that and how does he tell his 19 shareholders about how he's spending his money, their money. 20 MR. MERRITT: Well --21 THE COURT: That is bizarre, but, anyway, that's the 22 record. 23 MR. MERRITT: In any event, that is the record. THE COURT: Okay, you've got three, four, five, six, 24 25 seven, eight, nine, 10, 11.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

MR. MERRITT: And then factors 12, 13, and 14, 14, the opinion testimony has been stricken. 12 and 13, 12 is the portion of profit or selling price customarily allowed for use of the invention. We have no evidence on that. 13, the portion of realizable profit attributable to the invention is distinguished from non-patented elements, et We have no evidence on that in part for the reason I just explained to the Court. But in sum and substance, a very significant number of these Georgia-Pacific factors are present in the factual record and fully disclosed to everyone. THE COURT: What is the Dow Chemical case you are talking about? Have you got it right here? MR. MERRITT: Yes, sir, I do. I have so many things up here, it will take me a moment to pull it up. The case is Dow Chemical versus, I believe it's MMM or EEE. Here it is. Dow Chemical v. MEE Industries, 341 F.3d 1370. It's a 2003 decision. THE COURT: I know the case. I just don't have it. MR. MERRITT: I'm sorry. I can hand you up my one copy. THE COURT: Do you mind? MR. MERRITT: No, sir. THE COURT: I just need to refresh my memory. MR. MERRITT: I will turn it to the damages discussion.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

THE COURT: Thank you. They held that the opinion by this guy Pirc was admissible, didn't they? MR. MERRITT: They held that the opinion by Pirc was inadmissible --THE COURT: The district court held it. MR. MERRITT: Dow Chemical, on appeal, didn't challenge that. Dow Chemical made the argument that even without Pirc, we should be able to try this case and put on evidence of the Georgia-Pacific factors --THE COURT: What I'm talking about is they say -- the Court says, "Rather Dow urges that reasonable royalty damages can be awarded even without such testimony; that there is a presumption of damages where infringement has been established; and that there is other evidence in the record, including the evidence supporting Pirc's excluded opinions, that the district court must consider." So they never did hold -- they never did get to the point of Pirc's opinion --MR. MERRITT: That's correct. Because Dow didn't challenge that exclusion of Pirc on appeal. THE COURT: What happened when this case went back? MR. MERRITT: I don't know, Judge. Someone else here may know. I do not. THE COURT: They sure just didn't drop it. probably settled, I quess. MR. MERRITT: I simply don't know the answer to that

question.

THE COURT: All right.

MR. MERRITT: In any event, what I think this exercise is showing, and I just go back to -- I go back to my original point. It's interesting that our discussion has really not been about anything that has not been disclosed. Our discussion has been, really, about whether there's sufficient factual evidence in the record to permit this to go forward and for a jury to decide it.

That's why I expressed my initial concern about a Rule 37 motion being kind of a backdoor decision about sufficiency of evidence, and we do have a concern about that. We think the evidence is sufficient. This is all based on discovery that's been taken in the case with all counsel present. So that is our position on that.

THE COURT: Tell me how you're going to argue to the jury what the reasonable royalty rate should be and why isn't the presence of all this just utterly prejudicial and confusing on this record since they don't have any idea what a reasonable royalty rate should be? If you lose on the issue of GP, Georgia-Pacific three, and motion in limine number one is not moot but you lose it, you don't have any royalty rate particularly to point to. How do you prove -- how do you argue to the jury what a reasonable royalty rate is?

They're going to come back, and they're going to say,

Judge, you said a reasonable royalty rate, and any figure, any guidance for us on that? You have to remember what you've read or heard in the case. That's what I'd tell them.

MR. MERRITT: The guidance would be that you can't reach a number that's not supported by the record. And so they will have the total revenues that Lawson makes from selling these products, they'll have profitability information. They will have some sense that there is a ceiling on this.

I assume that a jury is not going to award more than somebody's profits on this, but under the law, on appeal of jury verdicts we've looked at in patent cases, infringement verdicts, as long as there is support in the record that it can be tethered to, are given a great deal of deference, and it's often the case that you have either competing royalty rates through experts, neither of which is chosen by a jury --

THE COURT: But they set a range.

MR. MERRITT: They do set a range. Certainly this evidence of revenues, profits, et cetera, we think it would be enhanced, frankly, by data points from other licenses of these --

THE COURT: How can I do that if I do what you urged me to do earlier, and that is find that *Georgia-Pacific* factor number two in the Green opinion is excluded, and that's one of his most significant factors? In other words, don't you all have to play by the same rules you want me to hold them to?

And then what happens? Does Mr. Green come in because all of a sudden *Georgia-Pacific* factor number two, and I was wrong in ruling on the motion *in limine* about rates for comparable patents being out? Does that bring Mr. Green back into the fold, or what does it do? You realize there's a lot of -- several different edges to this sword.

MR. MERRITT: There are, Your Honor, and I would simply point out two things on that. First of all, the rates that Green was referring to were for patents other than the patents-in-suit, and we do think that's an important distinction. The actual history of patents-in-suit, we understand you may have some views as to whether they ultimately get in, but in terms of which is more relevant to this case --

THE COURT: I'll let you all brief that.

MR. MERRITT: We believe that's appropriate.

THE COURT: You don't have in front of you --

MR. MERRITT: The other thing I will mention is I listened very carefully to Mr. McDonald's argument on Green, and he acknowledged, and we think it is a correct statement of the law, if there's no range that has been articulated by the expert, that doesn't mean there are no damages. He said that in response to one of your questions, and we --

THE COURT: I want to disapprise ePlus of this: That statute -- what is it -- 284?

1 MR. MERRITT: Yes, sir. 2 THE COURT: That statute doesn't supplant the rules 3 of procedure. 4 MR. MERRITT: We agree. 5 THE COURT: It says, and that argument I think maybe got abandoned by the time the rebuttal brief got there, but the 6 7 mere fact that statute says that doesn't control what pretrial 8 orders say and rules say, so I'm not going to be considering 9 that anymore. So if you have anything on that topic, just keep 10 it, if you will. 11 MR. MERRITT: All right. 12 THE COURT: Anything else? 13 MR. MERRITT: No, sir. THE COURT: Why don't we take a little break? 14 15 16 (Recess taken.) 17 18 THE COURT: All right, Mr. McDonald. 19 MR. McDONALD: Thank you, Your Honor. I'd like to 20 bring us back to basics here about what we're really talking 21 about, and Rule 37(c)(1) is what we're talking about and whether that sanction should apply here in precluding this 22 evidence of damages. 23 24 And as set forth in the Southern States decision, 25 they say the basic purpose of that rule is to prevent surprise

and prejudice to the opposing party. That's what we're talking about here today, because even after all the questions Your Honor grilled ePlus counsel on, what are you going to say to the jury, what is the damages in terms of Rule 26, what is the computation of damages, we still don't know. We don't have a royalty rate, we don't have a royalty base. We still don't know what they're going to ask the jury, and here we are. Discovery is long closed, experts reports are long done. We're on the eve of trial.

THE COURT: He said you do know the royalty base, it came from you and it was fully discussed in depositions and it is -- it is articulated they're not going to deviate from the figures in the Mangum report, so that you do know the royalty base that they're going to rely on. So you can't really claim surprise as to what the royalty base is or the royalty theory. What do you say about that?

MR. McDONALD: Well, what I say is, Mangum has his own opinion on that. He didn't simply cut and paste our figures. We answered some discovery about certain sales numbers, but as you know, we have a dispute over which of those SKUs should be in the case. We do have a dispute over maintenance and service revenues and things like that.

The point is, if you put aside Mangum's report, where was the disclosure of this ever, and who's going to say that this is the total --

THE COURT: What they're saying, as I understand it, is that they used Mangum's report as a supplementary response to interrogatory number 17 and to their disclosure obligations, and if you look at the information in answers that you gave -- that you supplied in your brief to the Rule 26 disclosure and to the interrogatory, it looks to me like that they did.

And then they say, well, there's no foul under -- no violation of Rule 26(a) if it was otherwise provided in discovery, and it was otherwise provided in the ways they've outlined, and it looks to me like it was otherwise provided.

We're talking about the royalty base now.

You know what the theory is. You're not surprised by the theory, are you? There is reasonable royalty, whatever that may be.

MR. McDONALD: The idea of a reasonable royalty, that's right, although their disclosures don't limit them to that.

THE COURT: Well, I know, but they're limited now because they haven't made --

MR. McDONALD: So we know that.

THE COURT: We can't -- it would be reversible error for me to find that they hadn't disclosed their theory to you, and so it sounds like they did satisfy, although not in the conventional way, but they satisfied the requirements of the rule that it be available, and they can't be sanctioned for not

providing the royalty base.

MR. McDONALD: I still don't have an identification of who the witness is, and that's one of the questions we asked them. That was our interrogatory in damages, who is the witness who's going to testify about this. They still haven't said who that's going to be.

THE COURT: The pretrial order has a list of the witnesses?

MR. McDONALD: I still do not know which witness they're going to call on this royalty base issue. They've never disclosed who that's going to be.

THE COURT: He said --

MR. McDONALD: I don't think that's the main battleground here, but I still think it's very unclear what they're going to do on that front.

THE COURT: They're going to put on evidence as to each of the factors that he identified, and he mentioned the witnesses. I didn't write them down, but he mentioned the witnesses who would be testifying.

MR. McDONALD: None of those had to do with the base, though. I didn't hear him say which witness was going to testify about the base.

THE COURT: The base is already there. Then they're going to put on the *Georgia-Pacific* factors. You've got the base, and you haven't been surprise by the base figures.

1 MR. McDONALD: Let's talk about the rate. 2 THE COURT: The rate issue here, it seems to me, 3 that's where the rub is. 4 MR. McDONALD: Rule 26(a)(1), I just got it here. Ιt 5 requires a computation of each category. The word "theory" isn't in here. Talking about was it a theory or not. I think 6 7 royalty would be called a category for purposes of the rule 8 here just to try to match things up. 9 You have to provide a computation. It's not enough just to say, here's a category. You have to give the 10 11 computation, and, obviously, the royalty rate is critical to that. We have all these myriad facts in this case, all sorts 12 13 of data points here and there that they have cited to now in their recent brief they did not cite in their disclosures 14 15 during discovery. 16 Our expert and their expert were working off purportedly the same set of facts. Our expert said it should 17 18 be a lump sum of \$800,000. Their expert said it should be this 19 running royalty of about \$28 million or so. It's not enough 20 just to say, here's a bunch of facts, figure out the rate 21 yourself, because there's, obviously, a lot of different 22 conclusions people can draw from the --23 THE COURT: What about the Dow case? 24 MR. McDONALD: Which one?

THE COURT: Dow v. MME Industry, and it says they

25

remanded it for the district judge -- it wasn't a jury, it was a district judge, it looks like -- "the district court expressed an inability to calculate damages after excluding the testimony of Dow's damages expert. Dow does not appeal the district court's exclusion of its expert reasonable royalty testimony. Rather, Dow urges that reasonable royalty damages can be awarded even without such testimony; that there is a presumption of damages where infringement has been established; and that there is other evidence in the record, including the evidence supporting Pirc's excluded opinions that the district court must consider, we agree."

Now, that's the federal circuit law. It is, to me, a very incomplete analysis because it does not say how one calculates a rate in the absence of any evidence about a rate, but I don't know what rates, what other information in the record from the excluded report was there. There may have been rates from other license agreements. Here, there isn't that.

MR. McDONALD: That's right. And I believe in that case, the *Dow* case, I believe the defendant did have some evidence on standard industry rates if I remember right, but I apologize, I don't have the specific cite to that.

THE COURT: I remember reading the case earlier, but I didn't find anything about the existence of other --

MR. McDONALD: I'll see if I can find that cite for you --

THE COURT: -- rates in the opinion here. I may have missed it in my quick review of it when I called and asked for it and had it handed up, but I didn't see anything. Does that make a difference?

MR. McDONALD: It might be, but I think the main issue in *Dow* is that Rule 37(c)(1) wasn't even at issue. There was no issue of have they made their proper disclosures here under the rules, do we apply what the rules mandate should be applied when somebody has information helpful to their own case that they don't disclose properly in discovery.

THE COURT: Part of that, they say, is your fault because the first time they even could have answered or complied with the 26 computation rule, 26(a)(1) computation disclosure is when they had information that they could get only from you all, and you all stalled in giving it to them until April 30th, right before the expert reports were due, and they didn't have any way of doing it.

MR. McDONALD: They had our sales information earlier. We supplemented our sales a number of times in part because you have quarterly deadlines that come up, and so Lawson has additional information.

THE COURT: What is this nonsense in your company about not being able to find out what profit by product is?

MR. McDONALD: They have profitability disclosed in their 10-Q and 10-K $-\!-$

THE COURT: But not by product.

MR. McDONALD: No. They don't keep it that way, as the testimony indicated. Lawson is a different company than ePlus. ePlus has this one little piece of it. It's a hardware leasing company, and it's got one or two percent of it that sells this procurement software. Lawson sells a whole suite of business software products for human resources, for your financial department, talent management they called something.

THE COURT: But when Ford sells Escapes, Explorers, Expeditions, Focuses, Tauruses and all those things, it's been my experience, on the bench and in private practice, that companies are generally able to figure out what the profitability of a particular product is.

Now, it wasn't unusual in the past for me to see costing done on a gross basis, that is they will take cost and they'll have an overhead -- they'll just assign a fixed burden to a particular unit, and that goes against all -- that particular percentage goes against all of their products when they are a diverse company.

Carpet companies, I know, have done that for years with -- they have 150, 200 different lines of carpets, and they don't calculate the costs by machine to run that thing, but they take the mill costs and allocate them and say that this is what the cost is, and each product here gets the same cost allocated to it. Surely your company does something like that.

1 MR. McDONALD: That's right. 2 THE COURT: Where is it? Your man said he didn't 3 know that. 4 MR. McDONALD: The question was profitability for a 5 particular product. 6 THE COURT: That's what I mean. 7 MR. McDONALD: He wasn't asked whether they took the 8 general allocation or not. THE COURT: What you do --9 10 MR. McDONALD: The jury's got some charts, too, where 11 he shows they were able to allocate --12 THE COURT: That's what you do. You take the sale 13 price of the product, and you allocate the charged amount, just say allocated X percent, and you figure out what that is of 14 your cost, and you subtract it from your gross. You've got 15 16 your net profit. 17 MR. McDONALD: They've got that information. They 18 cited a couple basic --19 THE COURT: Did you give it to them? MR. McDONALD: -- the financial fellow's deposition, 20 21 you know, where he was answering the question like a bean-counter was asking that specific question, but you haven't 22 had any motions before this Court that we haven't disclosed our 23 profitability. We have disclosed it in a way that Lawson keeps 24 those records. 25

With the suite sales, I just want to clarify, it's not quite the same as having a bunch of different cars, because when Lawson goes to a customer, typically the customer is going to buy a collection all at one time of the HR unit and the financial, et cetera. So they buy those things together kind of off -- it's not a la carte.

THE COURT: That sounds to me like obfuscation.

Here's the point: It seems to me like you complained about the theory, and you know what the theory is. You complained about the category. The category is reasonable royalty. You know what that is, so you haven't been surprised. You know what the royalty base is because it comes from your own figures, and they've given that to you in a number of different ways.

Now -- and that includes the underlying data that was in the testimony that's been excluded from whatever -- Mangum's testimony, so you're not surprised by that. It's the royalty rate that I think is the focal point of the inquiry. Don't you agree with that?

MR. McDONALD: I think that's the focal point.

THE COURT: All right, now, have you ever been in a case where you try just -- you say, here's the royalty base, and, jury, you go fix a rate?

MR. McDONALD: No.

THE COURT: I don't know how to do that.

MR. McDONALD: It would be asking -- it would be

forcing the jury to speculate on damages. I think the most analogous case on this and why you shouldn't do that is the Boston Scientific case that we have in our papers, because the facts were a little different because the plaintiff actually chose not to call their damages expert. But they tried to rely on some evidence in the case, including some other license agreements, as the evidence and just go to the jury on that. And the judge said, no, I'm not going to let you do that, because you're forcing the jury to speculate on damages, and I can't let the jury do that.

And that's particularly important, she said. It's exacerbated by the fact that the base at issue was so large.

THE COURT: Is that Judge Saris's case?

MR. McDONALD: Northern District of California. It was 550 F.Supp. at 1102. So she said, without the expert, it's too speculative to go to the jury. There the sales amount was stipulated to be 1.8 billion dollars. It's more than here, but here the base that ePlus is going after is in the range of 4-or \$500 million.

THE COURT: This Boston Scientific case, though, wasn't on a motion. It was on a Rule 37 motion, wasn't it? Wasn't it a Rule 50 motion?

MR. McDONALD: Yeah, I think so. But I think the logic still applies here, is that they are asking the jury to speculate. Here the Court has this gatekeeper role that they

are applying to scrutinize these damages experts to come in and make sure that the way they fit the facts to their damages has a firm and acceptable methodology, it's relevant to the facts. Here you meticulously carried out the gatekeeper role, and then ePlus says, well, let's just tear down the gates and the fences all around the gates and just let the jury run with it and do whatever they want.

THE COURT: Let mustangs run the plains.

MR. McDONALD: Exactly. And we're busy here at this one doorway when there's no fence around the door, so who cares what's going on at the doorway if they're running around the side doors and back fence anyplace they want. Obviously, it lets things go amuck, and to say that they're going to be able to do this through these witnesses, I think that's totally off base.

When they bring up, for example, these other settlement agreements, those were all lump sums. And so what is the jury supposed to do with that? Mr. Mangum had speculative sales numbers, but he at least tried to convert it into a percentage. There is no witness, no witness, Your Honor, who will be able to take those lump sums and convert those into percentages.

How do I know that? Their 30(b)(6) witness on the licensing, Mr. Farber, in his deposition, when I asked him about those other deals, he admitted he was unaware of what

Ariba's or SAP's sales were, the two big ones. He had no idea what their actual sales were.

When we tried to ask other questions about the negotiations, he was precluded due to attorney/client privilege. We've got no information anywhere in the record and no witnesses who are going to be able to take those lump sum numbers and do anything that would be helpful to the jury coming up with an appropriate figure here.

So for them to rely again on settlement agreements that we've already shown in prior briefing, the vast majority of case law there says should never see the light of day on the damages issue starting with the Rude v. Westcott decision but going well beyond that, and so they're going to throw those numbers out in front of the jury, throw Lawson's gross sales in front of the jury, throw Lawson's gross profits, I guess, in front of the jury and just say, you decide now what the right number is.

That is totally outside of the bounds of what's acceptable here. When we're looking at Rule 37(c)(1) now, to bring it back to there, we're comparing the prejudice to Lawson versus was ePlus substantially justified. There's five factors, but that's really --

THE COURT: Yes, but you can cross-examine on each one of these witnesses. You actually were -- some of them are your witnesses, and you took the depositions of the other ones,

so you are perfectly able to cross-examine on all the Georgia-Pacific factors here.

MR. McDONALD: Well, then, I guess we ought to throw away 26(a)(1)(iii) because you basically said they don't have to disclose a single fact that's tied into damages, because they didn't. They didn't disclose anything about the computation or the documents that would underlie that. They're basically saying that rule is meaningless, and you're saying, when we serve an interrogatory number 17 that says give us the specific support for your reasonable royalty rate, tell us who the witnesses are, who are the documents (sic), that they can totally ignore that and it doesn't matter. That would be the natural, the necessary consequences of what you are saying. I think the business objects —

THE COURT: That's what they're saying.

MR. McDONALD: Excuse me. I apologize. Don't want to go too far. I think that Business Objects case makes it very clear. There the issue wasn't whether the facts were out there somewhere in the discovery. The Court said they were seeking to introduce evidence of damages not disclosed in response to that interrogatory. That's the words at page 1356 out of the Business Objects decision.

The question isn't whether the facts are in the ether somewhere. You have to disclose them specific to the damages interrogatory, to the damages disclosures. That's the problem

here.

Everything that ePlus has shown you today really proves one thing. It proves there was no justification for them to not disclose that proposed royalty rate, a rate that they were seeking many months ago. They have these facts, they had their prior cases, they had a lot of experience, they've had other damages experts in their prior cases, all these things at their disposal.

They had a lot of testimony from Lawson. As we had pointed out in our briefing regarding Mr. Mangum, the vast majority of even the Lawson testimony that Mr. Mangum relied on goes back to 2009. It wasn't late-showing-up depositions. It was information they've had for a long time. Everything that ePlus went through today shows you they had no justification for not answering that question with some specifics during the fact discovery period much earlier with respect to their initial disclosures, with respect to interrogatory number 17. No computations, no documents, and no witnesses were placed in there the way they are talking about it today.

So if we could go forward a couple of slides here.

This is just our interrogatory 17, very specific here. I think

I heard ePlus --

THE COURT: Excuse me a minute. I'm trying to find the section here that he was relying on.

MR. McDONALD: Supplementation --

```
1
               THE COURT: About other disclosures otherwise
 2
     disclosed.
 3
               MR. McDONALD: Can you go to slide number six here,
 4
     please. I've got that here.
 5
               THE COURT: That's 26(e), isn't it?
               MR. McDONALD: One before this one.
 6
 7
               THE COURT: Parties who have made disclosures under
 8
     Rule 26(a).
 9
               MR. McDONALD: I think I have it up on the screen
     right now. Is that the one?
10
               THE COURT: Then it says, and it "must supplement or
11
12
     correct its disclosure or response: (A), in a timely manner if
13
     it learns that in some material respect the disclosure or
     response is incomplete or incorrect, and if the additional or
14
     corrective information has not otherwise been made known to the
15
16
     other parties during the discovery process or in writing."
17
               In other words, the rule allows a fair leeway in
18
     complying with the (e)(1) supplementations -- supplementation
19
     of responses under 26(a)(1) which -- it just says 26(a) or
     26(e), so why haven't they satisfied all of that except with
20
     respect to the rate?
21
               MR. McDONALD: Well, A, rate is a big deal.
22
23
               THE COURT: I understand that, but I'm trying to make
     an analytical approach to it here. They disclosed it all
24
25
     except as to the rate. In other words, this "has not otherwise
```

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

been made known to the other parties during the discovery process or in writing" takes care of the base and the theory issue, but it doesn't take care of the rate, you say. MR. McDONALD: Right. But even beyond that --THE COURT: Do you agree with that? MR. McDONALD: Yes, that's right. Still doesn't take care of the rate. THE COURT: Do you agree that it's been otherwise made known to you as to the base and the theory? You have to say yes. MR. McDONALD: Well, the theory, we know that they wanted at least a reasonable royalty, so I don't think that's, you know, really putting us on notice of what they want. I want at least the minimum. That's not disclosing anything really. THE COURT: Sometimes admission is good for the soul, just like confession is. MR. McDONALD: We knew that they were seeking at least a reasonable rate. THE COURT: You knew what the base was that they were going against because you provided the basic sales figures, and you do have some dispute about whether the base can include certain SKUs, et cetera, or not, but that's an issue for later in the day, but apart from that, you know what the base is. The real issue is you don't know the rate, and you don't know

it even today. 2 MR. McDONALD: That's the most important --3 THE COURT: Isn't that what your rub is? 4 MR. McDONALD: That is exactly right. Even with 5 their supplementations, they never tied -- the discovery requirements require them to indicate what they are going to 6 7 rely on to prove damages. That's what Rule 26 and our 8 interrogatory require. None of that stuff that was disclosed 9 was anything they designated as something they were relying on. 10 THE COURT: They now have put in exhibits, designated 11 exhibits for the trial; right? You have gone through that 12 process. 13 MR. McDONALD: Sure. THE COURT: What do the exhibits from the trial tell 14 you about what the rate is? The proposed trial exhibits --15 excuse me -- tell you? 16 17 MR. McDONALD: Nothing. 18 THE COURT: They haven't even yet told you -- how 19 about their contentions of fact? In the contentions of fact, 20 do they tell you, we now contend that based on these factors that Mr. Merritt is arguing today, the royalty rate ought to be 21 seven percent or between two and ten or something? 22 23 MR. McDONALD: No. 24 THE COURT: Nothing? 25 MR. McDONALD: Nothing. You asked that question to

Mr. Merritt a number of times, what's the rate. Remember what his answer was? Did he ever give you a number? No. Well, we're going to do this, and we're going to do that, we're going to do the soft shoe and the waltz up there, but he never gave you the number.

THE COURT: Looks like the two-step you were doing.

MR. McDONALD: I guess. It's behind the podium, so actually I guess I'm glad you didn't see any of it.

Even today, we do not know, Your Honor. That's really the crux of it. That percentage is a huge issue, and that --

MR. McDONALD: Times 400-, \$500 million, whatever that number is, so eight times B equals C. Well, if A is the base, B is pretty important to know, and that Boston Scientific and we know that, but that Boston Scientific case really highlights how that exacerbates the fact that you're doing something you shouldn't be doing which is to ask that jury to speculate, pick a number as a percentage times a huge number, and my client is supposed to prepare now for a trial that's a couple weeks away, maybe slightly longer, and they don't even know what that is.

We also don't know which are going to be the key facts they would rely on to support that, and we've never had a chance to take discovery to go after those particular key facts

now. I mean, obviously, just like the experts did, some facts are more important than others. We've got no idea which ones

THE COURT: Suppose I were to tell them to give you a computation by tomorrow, let you take the depositions in the next week or so, and as a sanction, confine them to a royalty of one percent, that they were -- I would tell the jury that if you find anything as a royalty of one percent at most or two percent or three percent, is that a permissible approach to this or not, or is that just so outside the bounds of the usual course of administration of sanctions that one should not take an approach such as that?

MR. McDONALD: I can always --

THE COURT: You can also say, that's goofy.

MR. McDONALD: I can always count on you to ask me questions I did not anticipate, and here's at least one of them today. My initial reaction is, it would be very tough to defend that because where did the number come from, whether one percent --

THE COURT: Tough to defend on appeal, you mean?

MR. McDONALD: Yeah. I guess that's what I mean.

Because if that number doesn't come from a particular place, it seems to me like we're all asking for trouble to have that in there.

37(c)(1) gives you very clear grounds, and you've got

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

precedent just to say it's all or nothing. So that, to me, the safe place to go with that. THE COURT: All right. Anything else? MR. McDONALD: Let me check my notes here, Your Honor, please. Sure. THE COURT: MR. McDONALD: If we could go to slide, I believe it would be 14. One more past this one. I just want to point something here with this list of evidence that they've given us that we're supposedly -- we are sophisticated counsel or company or whatever, we should have seen this coming, I guess. Well, a lot of the evidence -- what this slide here highlights is a lot of the evidence they now cite was evidence that Mr. Mangum totally ignored in his expert report. Lawson profitability information, he didn't even talk about it. So if you're wondering why this hasn't been a bigger issue before now, well, now you know. The commercial success of the patents, that's another thing they've talked about. All of a sudden now this is one of the things they're going to put in front of a jury. Again, Mr. Mangum didn't talk about it. Also, their motion in limine, I believe it was number nine --THE COURT: Did anybody else talk about it? MR. McDONALD: No, I don't think so, because nobody -- you need a nexus under the law even to make it

relevant to obviousness. Now, it was talked about in the context of obviousness. I do correct myself there.

When they say we answered an interrogatory that talked about commercial success, they leave out the part that the interrogatory actually had to do with obviousness, patent invalidity, not damages. So it was disclosed in that context, but they filed --

THE COURT: That can be also otherwise disclosed in the discovery process.

MR. McDONALD: Yes.

THE COURT: In answer -- a fact that appears in an answer to one question might just as well be probative of another area. So the mere fact that it appears in a different interrogatory doesn't, I don't think, help you too much.

MR. McDONALD: Well, when their own expert doesn't even pay attention to it, though, it's pretty important, and when their own brief on motion in limine number nine to keep out evidence of their own commercial embodiment, when we brought up the issue, well, it might be relevant to damages, they said, well, we don't see how that would be relevant to damages, so what's the point of having this in for that reason. It's too prejudicial for that reason as well.

So they're talking about doing a 180 here on facts that previously had nothing to do with damages. All of a sudden now they're the kingpins of their case, and it's two

4

5

8

9

11

weeks from trial. That's exactly the sort of thing that Rule 37(c)(1) is designed to prevent. 3 THE COURT: All right. MR. McDONALD: Thank you. THE COURT: All right, Mr. Merritt. Anything else that you have? 6 7 MR. MERRITT: Your Honor, I know this isn't my motion, but there are a couple of points if I may address them. THE COURT: Well, I restructured the argument, and if Mr. McDonald feels like he'd like to say something in response 10 to what you say, he can have the last word. I'm interested in making sure, the best I can, of getting this right. 12 I think we're down to the real issue about what is it 13 that was ever disclosed about the royalty rate other than in 14 15 those -- I think there are rates -- there are no rates in any of the settlement papers except the one that's a running 16 royalty of five percent over \$15 million, and even then there 17 18 was a lump sum one I believe. 19 Anyway, what's -- I think we're down to what the 20 issue -- the reasonable royalty rate and how are they 21 prejudiced or not by the failure to say what that is. You haven't said it yet, have you? 22 23 MR. MERRITT: I have not. And in direct answer to the question, Your Honor, I'm not sure that we would have to 24 25 suggest a particular rate to the jury based on our reading of

the federal circuit cases, and we are getting down to the narrow point here: What are you entitled to present to the jury and what are they entitled to derive from the evidence in the record.

Frankly, we've all passed that point from different directions in this. If that's what this is down to, I know, I'm assuming a part of what you are suggesting that we do by tomorrow was maybe said in partial jest, but clearly it's the gut issue. I think the parties ought to brief that. Let's take a hard look --

THE COURT: Brief what?

MR. MERRITT: What we are permitted to put before the jury and what we're permitted to argue in closing and see what the law gives us guidance on on that. We believe, based on what we've looked at so far, that we can put in evidence that relates to the *Georgia-Pacific* factors and that a jury is able to take that, without us suggesting or telling them what the rate should be, and arrive at a royalty.

Remember, royalty can also be a lump sum. There's no magic under the law in having a rate. So we think we should just be careful about that issue and make sure we've got a handle on the law, and we've given the Court the benefit of what the law really provides.

THE COURT: They teed that up in their papers with the Boston Scientific decision, and I don't remember seeing any

response from you all -- and the ones also on the *Boston*Scientific, the page that discusses *Boston Scientific*, where is that? On page 13?

MR. MERRITT: I'm trying to recall where that is, Your Honor.

THE COURT: 13 of their brief, and then there's Lindemann, federal circuit, held that 284 does not mean that a patentee who puts on little or no satisfactory evidence of a reasonable royalty and, therefore, contravenes section 284 is entitled to damages I think is the --

MR. MERRITT: Lindemann and Boston Scientific we discuss at pages two and three of our brief in opposition. We like the statement of law in Lindemann very much. It starts at the bottom of page two of our brief and continues on three, that "when a 'reasonable royalty' is the measure" of damages, and the bracket is our insertion, "the amount may again be considered a factual inference from the evidence, yet there is room for exercise of a common-sense estimation of what the evidence shows would be a 'reasonable' award."

And then the Court in *Lindemann* goes on, "One challenging only the Court's finding as to amount of damages awarded under the 'reasonable royalty' provision of section 284, therefore, must show that the award is, in view of all the evidence, so outrageously high or so outrageously low as to be unsupportable as an estimation of the reasonable royalty."

Now, that doesn't say directly, but we are inferring from that statement that there is fairly broad latitude on the part of the jury to take a set of facts and to consider those, including profits, revenues, other things, even without, and again I go back to the hypothetical, what about the first case where there's no history of a royalty and if there's no comparable patents out there. A jury must have some ability, under section 284, to use the remaining *Georgia-Pacific* factors without being directed to a particular rate to derive a reasonable royalty.

THE COURT: You cite SmithKline. It says, "the factual determination of a reasonable royalty, however, need not be supported, and, indeed, frequently is not supported by the specific figures advanced by either party," but in that case and in every case I've seen where that was an issue, there was at least something to guide the jury in the exercise of a decisional process, and I don't see that SmithKline or Lindemann really say you can send to a jury just the raw data and have no basis for what the reasonable royalty would be.

MR. MERRITT: I guess what we're saying is -
THE COURT: Even now they don't know what you want,
and I don't know.

MR. MERRITT: Well, we do not believe, when it comes to a specific rate, that there is any authority for the proposition that under these circumstances, we must state a

rate.

THE COURT: Well, do you propose to go to the jury with an argument that's sort of like a personal injury case, that we've been infringed, here are the bottom line facts and you just do what you think is right, and then I have to deal with it on a post-trial motion from you if they come back at half a dollar or from them if they come back at \$500 million as outrageously high or low? You think that's the way it can go?

MR. MERRITT: In a general sense, yes. In terms of the post-trial handling of that by the Court, even if we gave specific rates, alternative rates through Mangum and Green who are both gone now, there's still the possibility that a jury could run in the wrong direction either way. I don't know how we eliminate that.

THE COURT: I understand that, but I'm saying, in other words, you're going to treat this like a personal injury case and say, give me what you think is fair.

MR. MERRITT: Well, I think it's not that loose.

This is not like pain and suffering. The fact is you're going to have a revenue base that will, by definition, contain at the top end what can be awarded. You're going to have profitability information such as it is even though it's product specific that's going to show what the profitability of this is which will be another containing factor.

You've got some tests that are in federal circuit law

which -- some of which have been criticized, by the way. The federal circuit, as we know, you can find cases that are intentioned on some of these points, but there's a 25 percent of profits rule of thumb that's been used in the past to look and see if a verdict is within a reasonable rate.

THE COURT: Do I tell a jury that as a practical matter, you should award damages no more than 25 percent of the profits?

MR. MERRITT: No, sir. We don't believe you should, but --

THE COURT: How does that play into this then?

MR. MERRITT: If a jury did come back with a figure that was too high, the Court felt was not supported in any way by the evidence -- let's say we took the \$600 million in revenues that these folks made from these products, and the jury came back and said, we're going to give you all \$600 million that they made of these products --

THE COURT: You'd choke on that, wouldn't you?

MR. MERRITT: We'd choke on that. We'd know what the likely result of that would be. However, the Court could look at that, and you could put us on terms, and it might use something -- and I'm not suggesting it's correct, but you might use something like the 25 percent of profits rule. In other words, there are ways to give the jury the latitude to use the evidence but to make sure that at the end of the day the jury

doesn't run out of bounds. But whether or not -- we are not aware of anything --

THE COURT: They don't even know what you're going to be doing. You haven't structured this even in your proposed -your contentions in the final pretrial order, Mr. McDonald
says. You haven't outlined even what you're going to do here
at this stage of the game. I mean, we still, right now, have a
trial set for one week from today, yesterday.

MR. MERRITT: Your Honor, all I can tell you is we have disclosed the facts that we believe would support a Georgia-Pacific instruction that would allow a jury to look at those and support a verdict. We, at this point, do not plan to propose a rate to the jury, but we do believe we can put evidence in from which a jury can derive a rate. We think the law permits that. We can understand why this is a --

THE COURT: Are you going to ask for a rate, or are you going to ask for a lump sum?

MR. MERRITT: We are going to say, these are the facts, and we are asking you to go back and award a royalty that you believe is supported by the evidence.

THE COURT: Either lump sum -- do I tell them it can be either a lump sum amount or a percentage?

MR. MERRITT: If, at the close of our evidence, Your Honor, you believe that instruction is properly supported, you could.

1 THE COURT: But isn't that what you have to tell a jury if you're doing it the way you're doing it? 2 3 MR. MERRITT: Yes, sir. 4 THE COURT: In other words, they have -- there are 5 two kinds of royalties that can be awarded. A reasonable royalty can be a paid-up royalty in which event you can tell 6 7 the jury, you can impose a reasonable royalty of some amount, 8 and for that amount, then the consequence of that would be that 9 Lawson would have a license to practice this patent until it expires; isn't that what you would tell them? 10 11 MR. MERRITT: Yes, sir. 12 THE COURT: And alternatively, you could establish a 13 royalty rate of some percentage, and what would I tell them it would be a percent of; sales, revenues, profits, what? How do 14 I do that? Ordinarily, it's profits, isn't it? 15 16 MR. MERRITT: Yes. You can determine what percentage of the profits you think could be awarded as a reasonable --17 18 THE COURT: I don't mean ordinarily, but it's one of 19 the ways because it's much easier to do it on sales because 20 it's a lower -- it's a different figure because --21 MR. MERRITT: It's easier to measure. 22 THE COURT: Because you know what the sales are. don't have a variable of cost accountancy coming in and 23 changing what the amount is. All right. Anything else? 24 25 MR. MERRITT: The only other -- these are very quick

points, and I don't want to belabor them because I do think we've gotten to the main point on this and identified it.

There were two statements that were made. I simply want to make sure you are deciding this, Your Honor, on a correct record.

The statement was made that Mr. Farber, when he was testifying -- Mr. Farber is an ePlus witness -- about licensing history, that he, in effect, asserted the attorney/client privilege and didn't respond to those questions. At least that's the way I understood the argument and the way I understand what's in the reply brief as well that Lawson filed at page three.

Just so that you'll be comfortable that he did not do that, we have included behind tab B, which I handed up, the relevant passage of Mr. Farber's deposition. What he was actually being asked during the deposition was about the licensing negotiations for SAP and Ariba. The point he was making was that at the time of those negotiations, because of a protective order that was in place, the revenues of SAP and Ariba were attorneys' eyes only, and he, as an ePlus executive was not permitted to see them.

At one point he misspoke, as a layman will sometimes do, and he used the term attorney/client in juxtaposition with confidential, but, clearly, there was no objection to his testimony based on attorney/client privilege, nor did he assert

it. We wanted that to be clear.

The other thing, a point was made about ePlus talking out of both sides of its mouth in connection with an earlier motion to exclude evidence. If you want to, Your Honor, just to confirm what the state of the record is on that, behind tab A, there are several orders that you entered on these various motions in limine.

The very last one, the last two pages behind tab A is the order that you entered with regard to motion in limine number nine that ePlus filed which is to preclude Lawson from proffering testimony, evidence, or argument improperly comparing the accused products in the commercial embodiments of ePlus and its predecessors for the purpose of proving non-infringement.

That motion was limited in that regard, and that is the order that you entered granting that motion and that motion alone. It did not mean that that evidence would not be useful by the parties for other issues in the case. So to the extent that it was suggested otherwise, we simply wanted you to have an accurate record on what your prior ruling had been. Those are my only comments unless the Court has any further questions.

THE COURT: All right.

MR. MERRITT: Thank you, Judge.

THE COURT: Mr. McDonald, you do have the last word.

MR. McDONALD: I'll try to keep it short, Your Honor.

THE COURT: Excuse me, before you start. What are
you suggesting briefing on? What did you want to file a brief
on?

MR. MERRITT: You have asked the question, Your

Honor, what -- I suppose one way to articulate it is, what is

the minimal argument that federal circuit law would permit us

to make to the jury on the question of a reasonable rate, do we
have to give them a rate, do we allow them to derive a rate.

It seems to me that that may be the point we're coming down to on all of this, and I'm not sure it's been grappled with directly. It's been touched on in the parties' briefs clearly, but I'm not sure it's been grappled with directly and fully, and it's a significant and important point that you may want us to take our best shot at before having to rule on that.

THE COURT: All right. I understand.

MR. McDONALD: Your Honor, just three points. One, with respect to the order on the commercial embodiments that's their tab A, the last order of Exhibit A, actually the Court did rule on using that information for purposes other than infringement.

Quote, to the extent that the proposed comparisons are offered for the alternative purpose of proving commercial success, the motion, motion to exclude, is granted because the

comparisons are of marginal relevance, and any probative value would be substantially outweighed by the risk of jury confusion and unfair prejudice under Federal Rule of Evidence 403. That was ePlus's request to keep out that information, so I want to clarify that.

On Mr. Farber's testimony, I did read and follow along with Mr. Merritt, and as I read it, I understood what he was saying. The witness did refer to attorney/client privilege, but I understand what he's saying. That probably wasn't really the right thing for him to say. The point, though, was he didn't get to see the information, and so how is he going to testify. That's the point.

If we're talking about the circumstances of the Ariba and the SAP settlements and he doesn't know the information,

Mr. Mangum's not testifying, nobody else can testify as to the actual facts either.

Finally, so Mr. Merritt is now saying they are not going to provide a computation of damages ever, right through the closing arguments. Rule 26(a)(1)(A) requires a party must provide a computation of each category of damages. ePlus's steadfast refusal, even as of today, and promise to the Court that even through closing arguments they will never comply with that rule pretty much mandates, in my opinion, that that damages theory should be excluded from trial under Rule 37(c)(1). Thank you.

THE COURT: When all is said and done, the issue here is a fairly simple one. The fact of the matter is that this motion is brought under Rule 37(c). 37(c)(1) has a test that's applied in the Fourth Circuit. The Fourth Circuit says, we consider the surprise to the party against whom the evidence would be offered, the ability of that party to cure the surprise, the extent to which allowing the evidence would disrupt the trial, the importance of the evidence, and the non-disclosing party's explanation for its failure to disclose the evidence.

In essence, what we have is no disclosure under 26(a)(1) other than that there was -- the plaintiff was seeking a theory of at least a reasonable royalty and that an expert would be, was being retained to work on that and get that straight.

The same basic answers were given to the interrogatory. Rule 26(e)(1) deals with supplementation of responses. It said, "A party who has made a disclosure under Rule 26(a), or who has responded to an interrogatory, request for production, or request for admission, must supplement or correct its disclosure or response, (A), in a timely manner if the party learns that in some material respect the disclose or response is incomplete or incorrect, and," "and if the additional or corrective information has not otherwise been made known to the parties during the discovery process or in

writing."

So what is it that we're talking about that wasn't disclosed? The royalty base is alleged in the -- the theory is alleged as non-disclosed. The base is alleged as non-disclosed, and the rate is alleged as non-disclosed, and the amount is alleged as non-disclosed, that is application of a rate to a base, either in the satisfaction of Rule 26(a)(1), which is computation of the damages, and that rule, (iii) says, "computation of each category of damages claimed by the disclosing party who must also make available for inspection and copying the documents or other evidentiary material on which each computation is based, including materials bearing on the nature and extent of injuries suffered."

So it looks to me as if the supplementation was accomplished here by the Mangum report, both as to the computation and the interrogatory answer. The Mangum report has been stricken as not in compliance with the precepts of Daubert and Kumho.

I don't think that applying -- I think applying the Southern States test, because that's the test that's applied, whereas here the allegation is that a party did not satisfy its disclosure obligations. If a party fails to provide information or identified witnesses required by Rule 26(a) or (e), the party is not allowed to use that information or witness to supply evidence on a motion at a hearing or at trial

unless the failure was substantially justified or is harmless.

And in addition to or instead of that sanction, the Court can do alternate sanctions and may impose other appropriate sanctions including any of the orders entered in 37(b)(2)(A)(i) through (vi), and that includes prohibiting the disobedient party from supporting or opposing designated claims or defenses or from introducing designated matters in evidence.

That is a drastic sanction foreclosing the testimony or prohibiting information in evidence. I don't think there's any surprise in the disclosure of the theory, and there's no surprise in the disclosure of the royalty base given the record in this case, for it was disclosed in a number -- it comes from Lawson's own figures, and Mangum has that information in his report.

So I don't think there's any need to go through the analysis of the ability to cure the surprise or disruption or importance of the evidence and explanation for failure to disclose, but much of the failure to disclose the royalty base lies at Lawson's own feet for dragging its heels in providing financial information that it was requested to provide.

The evidence is, however, important because it has a bearing on the ultimate damages in the case and the remedy that is presumptively one under 284 of the statute, and I'm not sure that evidence of the base would provide for disruption at trial.

That brings us to the question of the royalty rate or the reasonable royalty. The reasonable royalty amount can be a lump sum amount, or it can be a percentage. It has to be a percentage of something. As of this time, Lawson does not know what ePlus will actually claim. Therefore, we're on the eve of trial and the pretrial order has been prepared, and the contentions of fact that are recited in it and the contentions of law contain no indication of what Lawson would be required to meet, and in terms of what an amount -- that is claimed either by lump sum or otherwise.

I believe there would be a significant disruption of the trial in this fashion and a significant prejudice to Lawson in this fashion. As in *Boston Scientific* and the other cases cited by Lawson on pages 13 and following of its brief and is taught by *Lindemann* itself, where the record lacks any evidence of a reasonable royalty rate, the federal circuit has approved awarding of zero damages, and nothing in 284 exonerates a patentee from putting on evidence in support of an assertion, nor does nothing in 284 -- is there anything in 284 that changes the fundamental application of the disclosure and discovery Rules 26(a) and 26(e).

The evidence is critically important. The explanation for failing to disclose the evidence is offered by -- of the base is very hard to get a handle on, but it's -- I mean of the rate. ePlus has had jury awards of 37- and

\$17 million in settlements of a whole lot of other figures, so it could have posited a lump sum figure as a potential alternative. It chose not to do that.

I realize that it may be difficult to connect the two, and I realize that the base here is sufficient that perhaps a rate is a better rate, particularly if you can get a rate of the kind that Mr. Mangum was urging as applied against that base, but, in essence, it's fairly plausible, even after Mangum was excused, to supplement an interrogatory answer and say, we're going to at least ask for this, or, we're going to ask for that, and explain why, and I think at this stage of the proceeding, there would be a substantial disruption of the trial proceedings.

I would have to allow Lawson to take depositions. The parties, I will note, have so inundated the Court with paper and objections to things that it may be necessary to put the trial off, but it's not going to be put off by more than a week, and I'm not sure of that right now. So I believe that applying the *Southern States* calculus on balance yields the result that there will be no evidence permitted on the damages under the facts of this case.

That is not to say that in all cases a party has to have an expert to present its damages case. I think clearly Dow teaches us that is not the case, but a party must do what is required by the rules.

As I said, these rules were changed. This whole concept of disclosure was put in in 1993 for a reason. This one has a reason different than the experts. The reason here is to let the parties know at the outset of the case what the parameters of risk are all about, and the supplementation responses, requirements were imposed and underscored in order to make sure that the parties were kept abreast of the key issues in the case, one of which is damages as is evidenced by its occupying a separate disclosure provision in 26(a) and by the common-sense fact and knowledge that it's the money that drives most litigation in any event. That's particularly true in patent cases.

So I think on these facts, on this record, in the circumstances that this is presented, Lawson's motion has to be granted, and I understand the teaching of Lindemann and Dow Chemical against MME and the other cases cited by the plaintiffs in their brief, but this is a case where the inattention to the rules have created significant prejudice that I can't figure out a way to undo to Lawson. So that motion will be granted. It is now what, quarter to 1:00?

THE CLERK: Yes.

THE COURT: I need to talk with you all about this SKU question, and we have another expert -- whole issue of other expert reports as well, and I want to know some things about the trial that I have some questions on, so we'll take an

hour recess for lunch, and we'll be back and I'll hear the rest of it. Thank you very much.

(Luncheon recess.)

THE COURT: All right, we have the motion in ePlus to strike the expert reports of Staats and Knuth.

MR. ROBERTSON: Good afternoon, Your Honor. Scott Robertson for ePlus. Let me start by saying what we're not going to do here today, and that is reargue the motion in limine number five and get into what a discipline is again, Your Honor.

We accept the Court's ruling, and the question becomes, what did we understand was going to occur with the Court's order that the defendant may use one additional expert on the topic of source code and one additional expert on invalidity as to 102 and 103 issues, and what we decidedly did not expect was what has, in fact, occurred here, and, indeed, Your Honor will recall on at least a couple of occasions, I expressed my concern out of an abundance of caution with the Court as to this issue of doing overlapping reports or me-too reports or submitting reports on the same subject matter that had already occurred, and what we found here, Your Honor, was that's the situation we're in now.

If, at the end of that hearing, Lawson had stood up

and said, well, here's what we expect to do, Your Honor, in light of your ruling, and that is, we're going to wait about a month, and then we're going to issue a report that is 127 pages long with 474 paragraphs --

THE COURT: Who is that?

MR. ROBERTSON: That is Dr. Staats.

THE COURT: We're talking about Staats now?

MR. ROBERTSON: Yes, sir. That is identical on all the topics and the issues with respect to this anticipation and obviousness that Dr. Shamos had already opined on and that the plaintiff had taken Dr. Shamos's deposition in reliance on those opinions being offered. We had prepared Mr. Hilliard's responsive rebuttal report in reliance that those were going to be the opinions.

We then deposed Dr. Shamos, and then Dr. Shamos offered surrebuttal opinions with respect to that. And then what we're going to do, Your Honor, Lawson counsel would say, is right on the eve of trial, we're going to submit this report that completely swaps out Dr. Shamos for Dr. Staats.

And in Mr. McDonald's rather lengthy letter to you, he actually concedes that it's true that the subject matter of the Staats report substantially overlaps, if not entirely overlaps, the Shamos report.

So here we find ourselves, Your Honor, potentially on the eve of trial, with a completely new expert who we have not

deposed, who we have not filed a rebuttal report, who now has changed and modified and expanded on his opinions with respect to all of the prior art that Dr. Shamos had previously opined. We were offered a one-time-only deposition of Dr. Staats three business days after we received his report which we were not in a position to take, and we don't have a rebuttal report for Mr. Hilliard prepared, and if we have to, it's going to take great time and expense to go through this 127-page report with 474 separate paragraphs.

Now, I didn't certainly expect that. I don't think the Court expected that that was going to be the result of your order in motion in limine number five, that the defendant would get to simply drop its invalidity expert and introduce someone wholly new who, remarkably, however, as an independent expert, came up with the same ultimate conclusions that Dr. Shamos found with respect to all this prior art that's been offered.

Now, to be sure, Dr. Staats has expanded on many of the opinions of Dr. Shamos, and has, in fact, done what really would be characterized as a sur-surrebuttal to Mr. Hilliard who will now not have an opportunity to respond to those arguments unless, of course, the Court permits him to do so. I would suggest that this certainly was not what the Court intended when it was going to permit an additional expert on these issues of anticipation and obviousness.

And the prejudice to us at this late date as we're

trying to prepare for a potential trial where we would need rebut him and go take his deposition, probably do it the week before the trial or even during our case in chief, I think, is clear and manifest, Your Honor.

So respect to Dr. Staats and his effort at the last minute to run away from Dr. Shamos, who we had been relying on since he was disclosed and provided an expert report back in May, we think is wholly improper and clearly could not have been what the Court intended.

Now, to be fair, Mr. Knuth, if that's how you pronounce his name -- I believe it is -- is in a slightly different situation. The problem with Mr. Knuth's report, which, again, is 40 pages long and 125 paragraphs, the problem with his report, however, is instead of doing what the Court directed, that is meet Mr. Niemeyer's expert report, who was our source code report, he goes well beyond that and treads on top of and overlapping with Dr. Shamos's opinions.

And we went through at some length, Your Honor -this was fairly hastily prepared because I attempted to bring
it to the Court's attention the day after we obtained these
reports, but at page ten of our initial brief through page 13,
we show a number of instances, sir, where Mr. Knuth's opinions
substantially overlap with Dr. Shamos's opinions.

Now, Mr. Knuth also expresses opinions with respect to non-infringement positions. You will recall, and it's

represented in the papers, that Lawson concedes that Mr.

Niemeyer made no non-infringement arguments. He doesn't even address the claims, he doesn't address any of the contentions or the Court's construction. He simply looked at and interpreted the source code that is the accused source code for the accused product in this case.

Now, to be sure, Mr. Knuth, in some instances, in some of the 125 paragraphs, does, in fact, respond to some of the positions and opinions of Mr. Niemeyer. Again, Mr. Niemeyer will not have, unless the Court permits, an opportunity to respond to those, but to the extent that Mr. Knuth opines on non-infringement positions or, indeed, he goes on to opine on invalidity positions, that does not properly meet Mr. Niemeyer's report as the Court suggested was the proper scope of any report.

Of course, again, we're confronted with the same situation that these reports are provided to us on the eve of a trial, warrant a response, otherwise ePlus would be seriously prejudiced, and warrant the ability to take a deposition of at least Mr. Knuth if, in fact, he's going to go forward on his source code opinions.

Of the approximately 125 paragraphs in the report, I would suggest that about 60 or more are improper. Now, I'm probably a little biased here, but we have outlined a number of them, and in particular, one of my concerns is with respect to

his invalidity opinions. He attempts to get in through the back door facts and opinions that this Court has already excluded.

You will recall that there was a motion in limine with respect to version 5.0 and 6.0, and the Court has allowed evidence with respect to those systems for very limited purpose, and that was one element of one claim of the '683 patent.

Now, to be sure, Mr. Knuth does not expressly reference 5.0 and 6.0. In fact, Mr. McDonald said that in his letter to the Court. He was very careful to say that, because what he continues to do is talk about the prior systems, quote unquote, of Lawson, and continues to say that the prior systems could do X or the prior systems could do Y, and, indeed, you will recall that when we received the report initially, it referenced version 7.0.

Now, I had raised that issue again with the Court in a conference call, and it was represented that they would not be offering 7.0 in this report, so we were surprised to see it.

Now, afterwards, they did, the next day, produce a redacted version, but all it simply does is sanitize the report by referencing the 7.0. It still has numerous references to these prior systems --

THE COURT: You mean by deleting 7.0?

MR. ROBERTSON: By deleting the words. In fact, Your

Honor, I can hand you up a copy, if I could, of the redacted version which I believe opens at appendix D. In many instances, all they've done is just delete the reference to 7.0.

As you will see -- maybe I can give you some specific examples -- starting at page 12 of our initial brief, at the bottom of the page, you'll see there's comparisons between opinions that Dr. Shamos has already given and these opinions that Dr. Knuth gives on invalidity, again not meeting what Mr. Niemeyer addressed because Mr. Niemeyer never addressed any invalidity issues.

Here's what he says: I'm aware of earlier versions of the F3 software that included these modules dating back to at least the 1980s. They are talking about the 5.0 versions and 6.0 versions and other prior versions before 2002 that Your Honor said could not be admitted for any purpose other than this one narrow issue.

I can cite many more examples. In fact, they go on to the next page in which he continues to refer to these prior systems and the functionality, but Your Honor had ruled that it would be confusing, it's irrelevant, and it certainly does not meet the Niemeyer report who never addressed these issues at all.

So here we find ourselves, Your Honor, potentially on the eve of trial, where we would be severely prejudiced if we

have to go out and respond to these. I don't think it was in the spirit of the letter of the Court's rulings on these issues. Thank you.

MS. STOLL-DeBELL: Good afternoon, Your Honor.

THE COURT: Afternoon.

MS. STOLL-DeBELL: I think we need to go back and look at where we started from, and when I was here arguing before you on our motion in limine number five, we had two complaints about ePlus's multiple experts. The first was that there would be overlap between Mr. Niemeyer and Dr. Weaver on the infringement issues, and I have never conceded that Mr. Niemeyer is not giving infringement opinions. I can see that he doesn't use the word infringement, but I do believe gives infringement opinions, and I do believe that there's overlap between him and Dr. Weaver.

Our second complaint was the prejudice that would be caused to Lawson by ePlus having three technical experts when Lawson only had one, and we only had one because we were following scheduling order one-expert-per-discipline rule, and I believe I referred to it as the parade of ePlus's technical experts and our concern that the jury would find their positions to be more credible simply because they've got three experts and we have one.

And so what I understand Your Honor to order, what we all understood Your Honor to order, was to allow us essentially

to replace some of Dr. Shamos's opinions with two additional experts so that we would have the same number of experts as ePlus. There would be balance in the sides.

To talk first about Dr. Staats, we believe we were following two guidelines that you gave us. The first was that we were to rebut Mr. Hilliard's report, and the second was that we needed to stay within the confines of our second supplemental invalidity contentions. I think that was abundantly clear to us that we needed to do that, and, in fact, we did, Your Honor. Had we stepped outside, even with a toe outside of that contention, you would have heard about it from ePlus, but we didn't.

And so if you look at those things, I mean, if we have to stay within the confines of the second supplemental invalidity contention and rebut Mr. Hilliard, I mean, if we couldn't overlap what Dr. Shamos said, there would have been nothing for Dr. Staats to say because Dr. Shamos gave an opinion on everything that was in those second supplemental invalidity contentions, and more, which was stricken. So, you know, if you follow what ePlus says, then really there was no relief for Lawson at all because there was nothing that Dr. Staats would be permitted to say.

If we can go to slide five.

THE COURT: Is that the same book he handed up?

MS. STOLL-DeBELL: It is.

MR. CARR: There's a tab in the book.

MS. STOLL-DeBELL: There should be numbers on the bottom.

THE COURT: Staats, Knuth; which one?

MS. STOLL-DeBELL: Number five. So, you know, I guess, I would direct you to look first at slide number two.

That is where we started, Your Honor. We had one technical expert to deal with all of the issues in this case. We believe the relief that you granted us was to give us two additional experts, and we did, in fact, do that.

We are, in effect, replacing of some Dr. Shamos's invalidity opinions with Dr. Staats, and we do not intend to have overlapping testimony. Dr. Staats will talk about all of the 102 and 103 invalidity issues with the exception of the Lawson version five and version six for that one element of claim six of the '683.

The reason that we left that with Dr. Shamos is he's already going to be giving testimony about Lawson's software, and so it seemed to us much more efficient to have Dr. Shamos talk about the prior version of Lawson software which is similar for that one particular element of that one claim, and, frankly, we needed to find two additional experts after you entered your order, we needed to have them review the prior art, they needed to get up to speed, they needed to prepare expert reports, and so for that reason, it seemed to make sense

to have Dr. Shamos stick with that one particular aspect of section 102 and 103, but otherwise it will be Dr. Staats.

Now, ePlus, I mean they admit that Dr. Staats is giving the same 102 and 103 invalidity opinions as Dr. Shamos.

THE COURT: Same result, different reasons, they say.

MS. STOLL-DeBELL: I don't think it is different reasons. There are two different men who prepared two expert reports, but I think the reasoning is fundamentally the same. If you go to slide eight, I think the one example that they gave to show that it was what they called dramatically different reasoning related to the means for searching for matching items element of claim three.

I believe that both experts have fundamentally the same reasoning. They both say that PO Writer searched, did key word searching and could search for item description.

Dr. Shamos said that at paragraph 183 of his expert report. Dr. Staats says that at paragraph 249. They both cite the same PO Writer manual. They cite to the same section of that manual, and they even cite to the same page which has Bates number L0126945.

So, I mean, they both say this prior art reference could search for matching items. They didn't use exact words. That's because they each prepared their own report as is required by the rules. I don't think it would be proper for us to have Dr. Staats get up and testify about a report prepared

```
by Dr. Shamos. So, there is going to be some --
 2
               THE COURT: Excuse me one minute.
 3
 4
               (Brief interruption.)
 5
 6
               MS. STOLL-DeBELL: In any event, I think their
 7
     reasoning is fundamentally the same. I think their reports are
 8
     not verbatim because two different men prepared them, but, you
 9
     know, they are citing the same sections, they are saying it
10
     does the same thing, and it's just not fundamentally different.
     And I think that's the only example they gave of that, Your
11
     Honor, out, you know, I don't know, however many hundreds of
12
13
     pages of Dr. Staats' report there were.
14
               THE COURT: All right.
               MS. STOLL-DeBELL: So with that, do you have any
15
16
     questions about Dr. Staats' report?
17
               THE COURT: No.
18
               MS. STOLL-DeBELL: Okay. Moving on to Mr. Knuth, I
19
     think we had one guideline we were supposed to follow with
20
     that, and that is to rebut Mr. Niemeyer. As I argued to you
21
     when we were here before, we believe that there are substantial
     overlap between Mr. Niemeyer's report and Dr. Weaver's report.
22
     Both of them were talking about Lawson's accused software and
23
     how it works.
24
25
               One of the big issues for the infringement case is
```

whether Lawson software has catalogs. You've probably heard about it already, and it's going to be a central theme of this case and maybe the most important and definitive issue in this case.

Mr. Niemeyer talks about Lawson software having catalogs. He doesn't say the claim requires a catalog. He doesn't quote your definition of catalog, but he says it's got catalogs. And then Dr. Weaver talks about the catalogs and how that meets the claim elements. And so as we're trying to rebut Mr. Niemeyer, it becomes intertwined with Dr. Weaver.

I've got a good example of this. If you go to slide ten, these are all paragraphs from Mr. Knuth's expert report, and he is basically rebutting Mr. Niemeyer's opinion that Lawson software has catalogs, and through that he needs to -- he needed to get into or rebut some of the things that Dr. Weaver said as well, and so I think we did follow your guidelines is what I'm saying. We did rebut Mr. Niemeyer, and that required some rebuttal of Dr. Weaver, too, because they are so intertwined. They are both basically saying the same thing.

THE COURT: All right.

MS. STOLL-DeBELL: Regarding version seven, we think it is relevant, but we're trying to avoid this motion, Your Honor. We were trying to get ready for trial. They were upset by it, and we volunteered to pull it out to avoid this all, and

it wasn't good enough, and they are still arguing about it.

The fact of the matter is we pulled it out, Mr. Knuth will not talk about it at trial, and it ultimately didn't work and they still brought the motion, but it's out.

THE COURT: All right.

MS. STOLL-DeBELL: Then, finally, Mr. Knuth is not giving invalidity opinions. He's just not. He's talking about how Lawson software works. To the extent that he had brief references to Lawson's older software, again, it was to rebut Mr. Niemeyer and to rebut Dr. Weaver, and a good example of that is on slide 11.

Mr. Niemeyer talks about this software program called PO 536, and that is a way that Lawson came up with to automatically load data into their item master database, and you can see that as the first quote up there, paragraph 40.

Dr. Weaver also talks about PO 536, this automatic loading of catalog data, again showing that they both talk about the same thing, and he says that was first done in 2001.

Mr. Knuth came back and rebutted what Mr. Niemeyer said about that. He said, by the way, that's not true, it wasn't first done in 2001, we've been doing this functionality, and he went through and talked about how they've been doing it for a long time.

I think it was proper. I think it's rebuttal to correct the record and to correct the incorrect statements that

were made by Mr. Niemeyer and Dr. Weaver.

Finally, this deposition issue, when we were on the phone with you, and I think all along we told ePlus we would have the expert reports prepared by August 25th and that we would make these experts available to them for a deposition the week of September 30 -- or August 30 through September 3rd. We did, in fact, do that. We gave them as much notice as we could. We booked travel. I had travel. They had depositions set at ePlus's counsel's office in D.C.

I asked him twice, are you sure, we're making these witnesses available, they've got travel plans. Mr. Knuth was on a family vacation. He had plans to leave there so they could take his deposition, and they refused. So for them to get up and say they haven't had an opportunity to depose these experts is just wrong. We did everything that we could to make them available, and they refused to take them, and I don't think they should be permitted to stand up here and say that they are prejudiced because they can't take the depositions when clearly they could.

THE COURT: All right.

MS. STOLL-DeBELL: Are there any questions I can answer?

THE COURT: No, thank you.

MR. ROBERTSON: I'll be brief, Your Honor. Your Honor made something perfectly clear, and that was there was to

be no overlapping opinions. As I suggested to you starting at page ten of our initial brief, we've got side by side Mr.

Knuth's opinions on non-infringement and Dr. Shamos's opinions on non-infringement.

Right now I don't know who is offering what, but they're clearly overlapping. Dr. Niemeyer, Mr. Niemeyer never opined on any opinions regarding infringement. How do we know that? Well, two things. Here's Mr. Shamos's or Dr. Shamos's report at paragraph 179. Quote, Mr. Niemeyer does not express any opinions relating to infringement.

That's Dr. Shamos. Here's Mr. Knuth and his most recent report. Mr. Niemeyer does not state any ultimate conclusions regarding infringement. That's Mr. Niemeyer. So what are they doing responding if Mr. Knuth's report was only to address Niemeyer? What is he doing responding to Dr. Weaver repeatedly throughout that?

What Mr. Niemeyer was doing was simply looking at that time source code and saying the source code tells me the system has this functionality. He did not make --

THE COURT: What are you upset about if they don't have Staats and Shamos testifying to the same thing? Did you nail Shamos down pretty good, and you felt like you had a good opportunity to blow him out of the water, and now they've got somebody that's come in and corrected the foul-ups that he made in his deposition and giving them a better case? Is that what

this is all about on Staats? 2 MR. ROBERTSON: No, sir. I mean, do we --3 THE COURT: I would think that's what it would be 4 about. 5 MR. ROBERTSON: Do we feel we made some progress pinning Dr. Shamos's ears back? I think we did. 6 7 THE COURT: If I were making the argument, I'd say, 8 look, I had this guy nailed, and then they come in and they 9 don't like what he did, and, wham, they're replacing him, but 10 that doesn't seem to be the complaint, is it? 11 MR. ROBERTSON: No, that is the complaint, Your 12 Honor. 13 THE COURT: It is the complaint? MR. ROBERTSON: This is significant bait-and-switch 14 15 on us after we pinned down and spent considerable resources 16 pinning down Dr. Shamos with respect to his report, and now 17 here we are, and we have to do a complete do-over if this gets 18 allowed at additional considerable expense by having to have 19 our expert go back and look at it. Dr. Staats, in his report, also addressed more than 20 21 165 times Mr. Hilliard's rebuttal report, and Mr. Hilliard now doesn't get to respond to that. 22 23 My last final point is Mr. Niemeyer, neither Mr. Niemeyer nor Dr. Weaver have discussed this Lawson's prior art 24 system, so I don't understand why Mr. Knuth needed to go back, 25

especially in light of this Court's rulings with regard to the prior versions and reference those. Thank you.

THE COURT: I issued the opinion or the order that I issued allowing the extra experts for Lawson, and it never crossed my mind that one expert would be substituted for another, nor do I think that anything I said or did reasonably could have led to that result, and there was to be an expert who was to address just the source codes.

Now, what's happened is that Lawson has taken advantage of the situation, has gone well beyond what it is that I ordered and contemplated. I think I made that clear, and the bottom line is that Staats and Knuth aren't going to testify. I'm going back to where I was. I didn't give you all free rein to go out and get new experts and change the game at the end of the time. I was trying to allow some equity into a situation.

If, in fact, Knuth can testify just to source code, then I suppose it's all right to let him testify to that. Is there a part of his report where he testifies just to source code, and that's all, and responds to Hilliard -- is it Hilliard or Niemeyer? Niemeyer is the source code. Responds to Niemeyer?

MR. ROBERTSON: There are paragraphs, to be fair, Your Honor, that do that. Now, we might have a debate over which ones fairly respond to Niemeyer and which don't --

THE COURT: I'm talking about source code. I don't want him to get into prior versions, I don't want him to get into infringement or invalidity. What happens is when you get leeway from the Court, you better stay within it or you get smacked, and I'm not going back, and I'm not going to have the effort to be equitable turned into a 180-degree turn. I think that results in the application of the principle that he who seeks equity must do equity, and not that that's a guiding precept here, but, in essence, that's what I was trying to accomplish, and when you overstep the bounds at this stage of the proceeding, the only thing I can do is cut it out.

If Knuth can testify only on the meaning of the source codes, then he can testify. And that's all. The other guy, Staats, is not going to testify at all. Shamos has covered it all. You keep Niemeyer and Weaver out of the same patch of ground, and if you let them go in the same patch of ground, they're going to walk right out that door. Now, I mean you stomp all over that, and then there won't be any problem with it.

MR. ROBERTSON: I understand, sir.

THE COURT: That solves the problem.

MR. ROBERTSON: I would like to have a reasonable opportunity to review the report, respond to it, and take his deposition.

THE COURT: What have you been doing? You've been

studying to write these papers, so you've had time to review it.

MR. ROBERTSON: I've had some limited time to review.

THE COURT: Are you telling me that you worked all over the Labor Day weekend?

MR. ROBERTSON: Well, yeah, we were working over Labor Day weekend, Your Honor.

THE COURT: When do you want to take his deposition?

MR. ROBERTSON: Well, I'd like to take it -- I'd like to discuss it with the Court, the potential trial dates, and see if we can do it within a reasonable time frame prior to that so it doesn't interfere with case preparation or case in chief. I had a discussion with Mr. McDonald during the recess, and we wanted -- I understand the Court wanted to address some of those issues.

THE COURT: I've ruled on that. Now, you can take his deposition, and I'll work out a time. So, by the way, I don't think I said -- I intended to and I had a note to do it, but I don't know that I actually said in ruling on the motion to preclude damages evidence that for the same kinds of reasons set forth in Boston Scientific and the other cases cited on pages 13, 14 of the brief of Lawson, I believe there's a significant prejudice that emanates from having everything just thrown at the jury with no guidance and no structure, and that we leave a jury confused because there's no evidentiary

```
parameters to the opinion that they can possibly glean from
 1
 2
     what can be offered, and to that, what I said earlier, I add
 3
     that.
 4
               Now, I would like to know something. I haven't had
 5
     the time to completely go through -- I've read the pretrial,
 6
     final pretrial order. I haven't gone through all those
 7
     appendices. How many depositions and deposition designations
     are objected to? Approximately. A, how many depositions are
 8
 9
     you offering and how much --
10
               MR. ROBERTSON: I think there are nine in total, Your
11
     Honor.
12
               THE COURT: How many pages?
13
               MR. ROBERTSON: There's a few that are considerable,
     Your Honor, to be fair.
14
15
               THE COURT: Why are you doing that? Why don't you
16
     have the witnesses?
17
               MR. ROBERTSON: Most of these witnesses are coming
18
     live, I think for both parties, with the exception of some
19
     third parties.
               THE COURT: Why don't you just confine the
20
21
     depositions to the people you can't get here?
22
               MR. ROBERTSON: That's what we've done, sir.
23
               THE COURT: And you still have long depositions?
                               There's one or two in particular.
24
               MR. ROBERTSON:
25
               THE COURT: How long? What do you call long?
```

```
1
               MR. ROBERTSON: One is a third-party witness the
 2
     defendant is calling --
 3
               THE COURT: I'm talking about you. They can do their
 4
     own.
 5
               MR. ROBERTSON: 20, 30 minutes total for most of our
     third party --
 6
 7
               THE COURT: How much of that testimony is objected
 8
     to?
 9
               MR. ROBERTSON: Not a lot, Your Honor.
10
               THE COURT: So it's not going to take me long to rule
11
     on those objections then.
12
               MR. ROBERTSON: Not on those third-party customer
13
     depositions.
14
               THE COURT: On any of yours. I'm talking about
15
     yours.
16
               MR. ROBERTSON: That's it, Your Honor.
17
               THE COURT: How many exhibits did Lawson offer that
18
     you are objecting to?
19
               MR. ROBERTSON: Well, I'm going to give you my best
     estimate because I asked this very question, and the
20
21
     information I had on Friday, it was maybe -- over the weekend
     I've lost track. It was about 280 exhibits being offered.
22
23
     There are about --
24
               THE COURT: Of yours?
25
               MR. ROBERTSON: No, of Lawson.
```

THE COURT: All right, you're doing Lawson. How many of that 280 did you object to?

MR. ROBERTSON: Let me be clear. We have about 110 objections, but, Your Honor, many of the exhibits on the exhibit list -- let me just give you an example -- of Lawson, are, we think are exhibits that have already been handled by motions in limine in court. For example, something concrete specific, they have the reexaminations still on the list.

THE COURT: That's out.

MR. ROBERTSON: To be fair, they've indicated on a number of these that they recognize they are excluded. I don't want to speak for them, but I understand the argument to be that they want to have them on the list so they preserve the issue for appeal. I think Federal Rule of Evidence 103(a) takes care of that, because it's the subject of an order and it is preserved.

THE COURT: I'm perfectly happy to have them on the list and to say that the motion in limine disposed of them, and then I don't have to deal with them. If you take those out, how many objections, documents, exhibits do you object to?

 $$\operatorname{MR}.$$ ROBERTSON: Of the 280, I think it brings it down to about 60.

THE COURT: Are the 60 susceptible to grouping?

MR. ROBERTSON: Yes. In fact, we have tried to group some of those, and, you know, would be probably able to present

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

removed.

that grouping to the Court. I mean, certainly during pretrial, we would treat them in any kind of argument as grouped together, so for the convenience of the Court, it would suggest that a ruling on the logic behind this grouping would pertain to more than one document. I don't think we need to go document by document, that's for sure. THE COURT: Now, Mr. McDonald, how many -- wait a minute. Mr. Robertson, how many exhibits did you all --MR. ROBERTSON: We have approximately 390, Your Honor. THE COURT: And how many of those did they object to? MR. ROBERTSON: Ballpark is about 170, I think. THE COURT: Are any of them of the category that are on the list because they want to make sure that they know they are covered by the motion in limine? MR. ROBERTSON: I don't think we have any on our list they would contend are being excluded based on a prior ruling of the Court. Objections can be grouped together, and we have grouped them together. THE COURT: What are you going to do with 390 exhibits? MR. ROBERTSON: Well, Your Honor, a fair amount of exhibits may have pertained, or at least 20 or 30 may have pertained to the damages case, so I suppose they can be

THE COURT: Excuse me a minute. Are they ready? We don't have the lawyers here yet. Okay. Go ahead.

MR. ROBERTSON: We also worked out, I think, a stipulation with respect to one of the accused products. Just to be specific, there's an S3 product that's being accused and an M3 product. The parties have been working hard together to come to a stipulation that says, to the extent the jury finds infringement of the S3 product, there would be infringement of the M3 product. To the extent that the jury finds no infringement of the S3 product, there would be no infringement of the M3 product.

I think we're down to -- I think we may be in agreement on that. That removes another 20 or 25 exhibits. We are continuing to work to try to get these down to a manageable number.

THE COURT: If you all will leave the papers where you are and make room for the lawyers to sit there for a minute.

(Recess taken.)

THE COURT: The reason I'm asking these questions is to ascertain when the best time to have the final pretrial conference is, and what, if anything, has to be done about sliding the trial date a little bit. But the question I didn't

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

```
ask you that is pertinent to that is whether these depositions
that you're going to offer on both sides are on videotape,
because I'm going to rule off of the transcript, but you have
to edit the videotape to conform to the ruling. So are they on
videotape? Are all of them or some of them or --
         MR. ROBERTSON: I think all of them are, Your Honor.
         THE COURT: From both sides?
         MR. McDONALD: Yes. We have two, and I think one of
them may not have been.
         MR. ROBERTSON: That was telephonic, so I don't think
we videotaped it.
         THE COURT: How long are your depositions for Lawson?
         MR. McDONALD: The one that's not videotaped is very
       The other one that is videotaped is somewhat longer.
short.
I'm not sure if I can tell you in minutes.
         THE COURT: Half an hour, hour?
         MR. McDONALD: Somewhere between half hour and
45 minutes.
         THE COURT: How many objections did they lodge to
your two depositions?
         MR. McDONALD: I think there was a significant
number. Does that sound right? I was talking McLaughlin and
         That's the number of objections.
Fielder.
         MR. ROBERTSON: Fielder is a fair amount of
objections, Your Honor.
```

THE COURT: But if it's only 30 minutes, I ought not have too much trouble. All right, I don't think it will take longer than a day to do the final pretrial conference. Do you? You're going to have to -- let me ask you, you know, Judge Merhige had a rule, the wisdom of which I have just decided -- it has eluded me, but now I understand it. If you don't use an exhibit at trial, it's out. It's not in the record anymore.

I haven't ever done that before, but I'm about ready to do it. This is too many exhibits for a case like this.

500, 600 exhibits? Good grief. I've tried a 13-party multi-defendant case with fewer exhibits than that. So why do you have so many exhibits? Mr. Robertson, you have 390.

MR. ROBERTSON: I think now we're going to be below 300, and we're going to make an effort to whittle it down even more than that, but it's a fact-intensive case involving a lot of different facts that point to the infringement, and we need to draw upon that from a number of different documents and a number of different source code.

There are some documents that were fairly voluminous that we'll be removing, but still, with the infringement case, there is about -- excuse me.

THE COURT: Do you want to get some water? Do you want a cough drop?

MR. ROBERTSON: Water will do. We're going to make an effort, Your Honor, to get it down as small as we can, and

```
then I think -- certainly we don't want to be cumulative and
     gild the lily, but there's a number of documents that are
 2
 3
     relevant to the infringement case.
 4
               THE COURT: You know, Rule 611 is one of the most
 5
     often used rules in the Eastern District of Virginia.
               MR. ROBERTSON: I was not aware of that. One of the
 6
 7
     things we're going to try to do is Federal Rule of Evidence
 8
     1006 summaries for a number of these documents.
 9
               THE COURT: That's fine. All right. I'm not sure
10
     this is going to be a particularly long final pretrial
11
     conference in any event. So we have the time reserved on the
     13th to start the trial, but do we know, Mr. Neal, if this --
12
     do we a motion to dismiss tomorrow?
13
14
               THE CLERK: Yes, sir.
15
               THE COURT: Cullen?
16
               THE CLERK: Yes, sir.
17
               THE COURT: That's 9:30, isn't it?
18
               THE CLERK: Correct. Actually, no, it's not correct.
     10 o'clock, I have. It might take an hour and a half, multi
19
20
     defendants.
21
               THE COURT: Oh, yeah. I do remember. It's a lengthy
22
     RICO case, isn't it?
23
               THE CLERK: Yes, sir.
               THE COURT: Then the suppression motion is going to
24
25
     take most of the morning --
```

THE CLERK: That's scheduled for two hours at least.

THE COURT: And I have to do that.

THE CLERK: You have a competency hearing at one

o'clock.

THE COURT: Wednesday and Thursday, I can't do it, but I don't think it's going to take you too long to conform your rulings on objections, so we could have the pretrial conference the 13th and start, say, the 15th. But you have a problem with a deposition, I believe, you need to take of Mr. Knuth on the subject of the source codes. How long will that take to take?

MR. ROBERTSON: I don't anticipate it would take longer than seven hours, Your Honor, but, Your Honor, you did ask on a conference call we had, I believe last Friday, to check on certain dates and availability. I did check on the week of the 20th, and then you had also suggested that because the WiAV case had settled that there might be some openings on that.

One of the issues I have is, and I want to bring it to the Court's attention, because I did reach out to all of the witnesses. Dr. Weaver, you know, has been in some ill health because of cervical spinal issues, actually had scheduled a procedure, a nerve block for the week after the trial was supposed to conclude if it started on the 13th.

It's long-standing, would be difficult to move, and,

quite frankly, he doesn't want to move it because he wants to relieve the pain he's been suffering for a long time. 2 THE COURT: Where is his doctor? 3 4 MR. ROBERTSON: Charlottesville, I believe. 5 THE COURT: He can't move it up? 6 MR. ROBERTSON: I can look into that, but, I mean, he 7 told me it was a long-standing situation. I also have an issue 8 with one of my inventors who had taken time off from work for the week of the 13th. Now he's having difficulty getting time 9 off for the week of the 20th. I have spoken to Mr. McDonald --10 11 THE COURT: What does he do? 12 MR. ROBERTSON: He's a computer consultant, I 13 believe. He works for a company -- it's not independent. THE COURT: Well, if he's going to be available on 14 the 13th, he can be available the week of the 20th. 15 16 shouldn't be any problem. 17 MR. ROBERTSON: We have the issue with Dr. Weaver. 18 THE COURT: That's a legitimate issue. 19 MR. ROBERTSON: I was talking to Mr. McDonald about, you know, towards the end of October. Full disclosure here, 20 21 the one other issue that is standing out there is that Mr. Hilliard, his wife is a state court judge in Arizona. In fact, 22 she sits in the former Sandra Day O'Connor seat before she was 23 elevated to the bench. She has not had a vacation in a year, 24 25 and she scheduled a vacation in mid October. Dr. -- Mr.

```
Hilliard informs me that while he can't --
 1
 2
               THE COURT: It's not unusual that judges don't have
 3
     vacations.
 4
               MR. ROBERTSON: He has told me that under penalty of
     divorce, if he does not go on this long-planned, over a year,
 5
     vacation -- in fact, her whole staff and her law clerks are
 6
 7
     taking that same period off. So he can't really move that, but
 8
     he could be available, as he indicated to me, the second week
 9
     which is really when he would be necessary since he is our
10
     rebuttal to the defendant's invalidity case.
               THE COURT: I think WiAV was set to start on the 18th
11
12
     of October is what I was talking about. Isn't that right?
13
               MR. WILLETT: That's correct, Your Honor. Jury
     selection on the 14th and opening statements starting on the
14
15
     18th.
16
               THE COURT: The 18th, and we stopped -- we will not
17
     have the 21st.
18
               MR. WILLETT: That's correct.
19
               THE COURT: 21st is a bench/bar conference here that
20
     I'm leading.
21
               MR. ROBERTSON: I've just been informed that Mr.
     Hilliard and his wife are gone from the 14th through the 28th.
22
23
               THE COURT: Where are they going?
24
               MR. ROBERTSON:
                              Europe.
25
               THE COURT: Well, the 28th is a Thursday.
```

MR. ROBERTSON: We could start on the 25th, is what I was suggesting, Your Honor, and then the second week he could be back.

THE COURT: Except that I have a very long trial starting in November. You're not the only people on the docket.

MR. ROBERTSON: Understood, Your Honor.

THE COURT: So why don't we just go on the 13th then, and you all can take -- or the 14th. I'll do the pretrial conference on the 13th. You all can pick the jury on the 14th and take the deposition of Mr. Knuth this week, take it over the weekend, and we can go ahead and stay reasonably to the schedule.

MR. ROBERTSON: I'd prefer the 20th, Your Honor, if you were going to do that. That way Dr. Weaver can still be here.

THE COURT: I thought you said Dr. Weaver was going to have a procedure the 20th. The 13th is the first week, the 20th is the second week. Do you have any problems with starting it toward the end of October?

MR. McDONALD: I didn't really check late October. I know we talked about mid October for things, but as far as I know, I don't have any issues that I can't deal with, Your Honor. I know the closer we are to September 20th, the better, because that was communications I was able to have over the

1 weekend. THE COURT: September 20th, and then starting 2 3 October 18th for those two weeks. 4 MR. McDONALD: I don't think I have any problems with 5 that. 6 THE COURT: But he can't do it because one of his 7 experts is out of town. What we could do is start on the 18th, 8 and then your fellow could come back, fly into Washington here 9 and/or Richmond to come to testify on the 29th. 10 MR. ROBERTSON: I'll check, Your Honor. I haven't --I can't speak for him right this second. I will make every 11 12 effort if that, in fact, does not interfere with the plans, 13 travel plans. THE COURT: The real problem with that, Mr. 14 15 Robertson, is he might be non compos mentis after a flight of 16 seven and a half hours. The time might not be very impressive. I would think that, having just done it, I think -- how old is 17 18 he? 19 MR. ROBERTSON: He's in his early sixties. 20 THE COURT: So he's a young man. 21 MR. ROBERTSON: Yes, sir. THE COURT: The other thing is that I have a long 22 four-day criminal trial at the end of October that, for now, is 23 24 going. 25 THE CLERK: What date is that?

THE COURT: 26th. Is that still on? 1 2 THE CLERK: Are you talking about the --3 THE COURT: Erickson. 4 THE CLERK: It's still on, yes, sir. 5 THE COURT: Also Cunningham, but I think that's going 6 away. 7 MR. McDONALD: Your Honor, given Mr. Weaver's 8 situation, I think you mentioned one possibility is maybe at 9 least starting the middle of the week of the 13th of September. 10 If you did that, I think maybe Mr. Weaver could testify before 11 his surgery, because that's the week of the 20th, and we can 12 kind of stay closer to the schedule. I know my people are still available. 13 THE COURT: Why don't we do that. You make Mr. Knuth 14 available. Is he only going to testify on very limited parts 15 16 of his report? You make him available even if it has to be Saturday and Sunday. Then we'll have -- I've got -- we'll 17 18 start this pretrial conference at -- how long into your case does Weaver testify, does he go, and is he supposed to sit 19 20 through the testimony of the other case in order to be 21 available for rebuttal, or what is all this -- what does this 22 do to your case, I guess, is part of what I'm trying to find 23 out. Are you planning on having him sit through the whole trial, A? Let's try that. 24 25 MR. ROBERTSON: I don't think so, Your Honor, no.

1 THE COURT: When in your case are you going to put 2 him on? 3 MR. ROBERTSON: Typically maybe perhaps the beginning 4 of day three. He is a rebuttal witness, Your Honor, so there is probably aspects of testimony he's going to need to see, but 5 to answer your question, I don't think I'm going to be having 6 7 him sit here the entire time. 8 He also probably will want permission, if Your Honor 9 would allow, to occasionally get up from the witness chair. 10 Sometimes he does that so he can --THE COURT: He can stand up. He can do anything he 11 wants to do. Chief Justice Rehnquist used to stand up and go 12 behind the curtains his back hurt so bad. 13 I'm still lost. If he's having this problem, when is 14 he having the procedure, and how long is he out of commission? 15 16 MR. ROBERTSON: He indicates to me he won't be out of 17 commission very long. 18 THE COURT: What is very long? I don't have that on 19 my calendar. MR. ROBERTSON: He indicated to me it wasn't going to 20 21 be a problem for him to attend the trial if scheduled during the WiAV slot, but then I have the Hilliard problem although he 22 could come back for the second week. 23 THE COURT: I thought he couldn't because he doesn't 24 25 get back until the 29th.

MR. ROBERTSON: I don't have a calendar in front of 1 2 me. 3 THE COURT: What's wrong with you people coming to 4 court without your calendars? Is it some problem because you 5 keep electronics and we take all your electronics? Is that 6 what your problem is? 7 MR. ROBERTSON: I think I was perhaps mistaken --8 THE COURT: Do we have a calendar that he can look 9 at? 10 THE CLERK: Sure. 11 MR. ROBERTSON: My understanding was, Your Honor, I 12 guess what I was targeting was the week of the 25th and the 13 week of November 1st, and that way Mr. Hilliard could be back for the week of November 1st. 14 15 The real problem with that is I have a THE COURT: 16 criminal, four-day criminal trial in there. I don't know 17 whether it's going or not. Can you call the docket on that 18 case? THE CLERK: What is the case number? 19 20 THE COURT: I don't have any idea. Look on 21 October 26th, his calendar, and give him the docket number of the case. 22 23 MR. McDONALD: U.S. v. Darrel? 24 THE COURT: Erickson, October 26th. Bring him his book. 3:10CR6. Is that Ms. Cardwell's case. 25

```
1
               THE CLERK: No, sir, that's Ms. Taylor's case. That
 2
     was gone.
 3
               THE COURT: We had to put that off because the
 4
     witness was in Iraq or something. I think that's --
 5
               THE CLERK: You had a motion to suppress in that
 6
     also.
 7
               THE COURT: She withdrew that.
 8
               THE CLERK: Okay.
 9
               THE COURT: I think that case is going to trial, and
     it's set in that particular slot, so that week is not
10
11
     available.
               THE CLERK: That case is definitely going to trial.
12
13
               THE COURT: Yes, it is. I know it is. All right.
     You can do without Hilliard, or you can start early. You can
14
     start next week sometime, or it has to go into -- I have to
15
     start it -- how long is your case going to take, Mr. McDonald,
16
     do you think?
17
18
               MR. McDONALD: About four days, Your Honor.
               THE COURT: How long is yours going to take?
19
20
               MR. ROBERTSON: About five days, Your Honor.
21
               THE COURT: I think what I'm going to do is give you
22
     all each three days, and that's going to be the end of it.
     It's out of hand. You didn't take that long to try it before
23
     Judge Brinkema when you had damages.
24
25
               MR. ROBERTSON: Judge Brinkema's case was bifurcated,
```

so we didn't have --2 THE COURT: How about the Ariba case? 3 MR. ROBERTSON: That was the Ariba case. THE COURT: I mean the SAP case. 4 5 MR. ROBERTSON: Bifurcated. THE COURT: How long did you take to try that? 6 7 MR. CARR: I believe that went to day 15, Your Honor. 8 THE COURT: That's just too long to be talking about 9 trying a patent case. 10 MR. ROBERTSON: Your Honor, to be fair, I think four 11 of those 15 days were the jury deliberating. 12 THE COURT: All right. Then that's going to move you 13 to -- that moves you to early December. So, what do you want to try to look for? If I give you, carve out two weeks in 14 November, can you do that and confine it to two weeks? 15 16 MR. ROBERTSON: Yes. 17 THE COURT: That's all you're going to get. It's 18 going to be done and over. That means instructing the jury and 19 arguing at the end of the second week. 20 MR. ROBERTSON: Understood. 21 THE COURT: So you're going to have to split the time 22 accordingly, because I can't go beyond that. Otherwise, you're 23 going into next year. 24 MR. ROBERTSON: Understood. 25 MR. McDONALD: I'm sorry, what were the dates, the

```
two weeks, Your Honor?
 2
               THE COURT: Start November 1st.
 3
               MR. McDONALD: Ms. Stoll-DeBell's son has eye surgery
 4
     on the 2nd. At this point, that's an issue.
 5
               MS. STOLL-DeBELL: We've already waited for four
     months to get the surgery date that we have. So --
 6
 7
               THE COURT: I don't want you to have to wait for a
 8
     child's surgery. It's very hard to get.
 9
               MS. STOLL-DeBELL: It is. It's ridiculous how long
     you have to wait, actually.
10
11
               THE COURT: If you think it's bad now, you wait. I'm
12
     not going to make her give up -- she's in the trial. I'm not
     going to make her give up her child's surgery. I expect you
13
     have to be with him a little bit after it's over.
14
15
               MS. STOLL-DeBELL: He's only one and a half, so, yes,
16
     Your Honor.
17
               THE COURT: So that kind of brackets things, folks.
18
               MR. ROBERTSON: What was the date in December Your
19
     Honor was suggesting?
               THE COURT: Well, I hate to do that because you're
20
21
     going to be really time limited there because I'm leaving on
22
     either the 16th or 17th. Looks like maybe it's the 17th, and
     the first week would be the 29th of November through
23
     December 3rd, and then the next week would be the 6th through
24
25
     the 10th with some possibility of overlapping into the 13th,
```

```
but --
 1
 2
               MR. McDONALD: I think we can make that work, Your
 3
     Honor.
 4
               THE COURT: Is your child going to be in a position
     by that time where you can --
 5
 6
               MS. STOLL-DeBELL: Yes.
 7
               THE COURT: -- be back in business?
 8
               MS. STOLL-DeBELL: Yes.
 9
               THE COURT: I'm still willing to try to do it next
10
     week.
11
               MR. ROBERTSON: Given how I think things are right
     now, that's very difficult, particularly with this -- this
12
13
     Knuth deposition is going to be pretty dense even limited to
14
     source code.
15
               THE COURT: Tense or dense?
16
               MR. ROBERTSON: Dense, sir, complex.
17
               THE COURT: I thought you used that just to describe
18
     judges, not to describe depositions. All right, but we need to
19
     do the final pretrial conference then.
               MR. McDONALD: Your Honor, I know we'll probably
20
21
     reduce the issues for the pretrial conference in view of
     today's ruling.
22
23
               THE COURT: I think so.
24
               MR. McDONALD: So it doesn't matter how quick we can
25
     do that, given the trial date, I don't know if you want to move
```

it out further or less, but I know we can consolidate things if 2 we had a little time. 3 MR. ROBERTSON: I will say the parties have been 4 meeting and conferring almost on a daily basis, and we've been 5 making substantial progress. 6 THE COURT: I hate to let you stop making substantial 7 progress, so I'd like to go and get the pretrial conference done while it's all fresh in your mind and I know you've got 8 9 some time available, and I realize you may have some minor 10 adjustments based on the Knuth deposition, but let's get the 11 final pretrial conference done the week of the 13th sometime. How about the 14th or the 15th, either one, or the 16th? 12 13 MR. McDONALD: Yes, Your Honor, that's fine with us. MR. ROBERTSON: Fine for plaintiff, Your Honor. 14 15 THE COURT: Let me tell you something. Just in case 16 it has to go over, let's do it on the 15th, and if it goes over, then you've got -- I don't have to change sentencings. 17 18 THE CLERK: Beginning at what time? 19 THE COURT: Why don't we begin at 10 o'clock, because 20 I have a supervised release at that time and it won't take 21 long. November 29th is the -- that's the Monday after 22 Thanksgiving. 23 THE CLERK: Correct. THE COURT: That really is not a good time for 24

witnesses and everybody else to be traveling and yours and

25

```
everything, so why don't we start on December 1st. Just know
 2
     that this case will be over by the 14th even if we have to go
 3
     on Saturdays, okay?
 4
               THE CLERK: Your Honor, considering the time of the
 5
     year that it is, we may want to have additional jurors.
 6
               THE COURT:
                          Okav.
 7
               THE CLERK: So we're going to start on the 1st?
 8
               THE COURT: The 1st. I think it's kind of hard on
 9
     jurors to get them in here and get them going the day after
10
     Thanksgiving.
11
               THE CLERK: And run through the 15th, is that what
12
     you said?
13
               THE COURT: 14th. And you all can talk about how you
     want to divide up the time. Is there anything else that needs
14
15
     to be done today?
16
               MS. STOLL-DeBELL: Yes, Your Honor. I just want to
     clarify that we still need to call Dr. Staats as a fact witness
17
18
     and wanted to make sure that your order was limited to him
19
     testifying as an expert.
               THE COURT: Expert. I didn't -- that motion wasn't
20
21
     directed to him testifying as a fact witness.
22
               MS. STOLL-DeBELL: I just wanted to clarify, make
     sure we're all on the same page.
23
24
               THE COURT: That was my understanding. Now, this SKU
25
     business, I've been studying this. I don't see how I can rule
```

on that until I hear the evidence, because each of you have a different view, but, in essence, you have to approve the predicate in your case in chief, and if you don't, then some of them may fall out, some of them may not, but the issue is accused products, not accused SKUs, and the fact of the matter is that you have control over the SKUs yourself on your side, and I think with the damages, with there being no damages in the case, the nature of the situation changes considerably, and the issue really becomes what is it that infringes and then what is it that is subject to the injunction that is going to issue if there's infringement that's proved. And I think that just requires some factual evidence that it would be premature to rule on that issue right now. It would amount to summary judgment on infringement, I think. Does anybody disagree with that?

MR. ROBERTSON: I think your ruling, Your Honor, on the damages issue potentially may resolve the SKU issues. I'd like to go back and discuss with my colleagues, but Mr. McDonald and I talked about it during the break, and it may be mooted in some sense.

In another sense, part of the commercial success of the accused products, that being, in essence, the royalty base that we discussed at length today, is relevant to one of the factors of nonobviousness. So maybe perhaps we can come to agreement on it and remove that issue from the Court's plate.

ı	1
1	THE COURT: All right. For now I'm denying that I
2	think it's your motion number two? Yeah, Lawson's motion
3	number two, I believe it is. Whichever one it is, I'm denying
4	it as without prejudice to raising a motion at trial on Rule 50
5	if it's appropriate. All right, is there anything else?
6	MR. ROBERTSON: Not for the plaintiff, Your Honor.
7	THE COURT: Let's plan to do this: Let's plan to
8	select the jury on the 29th in the afternoon on that case.
9	Then you can start your trial or evidence.
10	THE CLERK: 29th, you said the afternoon. Did you
11	say a time?
12	THE COURT: Let's start at 1:30.
13	THE CLERK: All right, sir.
14	THE COURT: All right, is there anything else that we
15	need to do? All right, we'll be in adjournment. Thank you.
16	
17	(End of proceedings.)
18	
19	
20	I certify that the foregoing is a correct transcript
21	from the record of proceedings in the above-entitled matter.
22	
23	
24	/s/ P. E. Peterson, RPR Date
25	1. 1. 1000150H, KIK